

## Curriculum Vitae for: Michael J. Schell, Ph.D.

Date: November 16, 2018

**Current Position:** Senior Member, Biostatistics and Bioinformatics Department  
Chair of the Appointment, Promotion & Tenure Committee  
H. Lee Moffitt Cancer Center & Research Institute  
12902 Magnolia Drive, MRC-Bio2  
Tampa, FL 33612-9416  
(813) 745-6061  
(813) 745-6107 (fax)  
[Michael.Schell@moffitt.org](mailto:Michael.Schell@moffitt.org)

### Current Academic Appointments

Professor  
Department of Oncologic Sciences College of Medicine  
University of South Florida  
12901 Bruce B. Downs Blvd.  
Tampa, FL 33612

### Education

1981 - 1984 Ph.D. Statistics, Florida State University, Tallahassee, FL  
1979 - 1981 M.S. Statistics, Florida State University, Tallahassee, FL  
1975 - 1979 B.S. Mathematics, University of North Carolina, Charlotte, NC  
1975 - 1979 B.A. Sociology, University of North Carolina, Charlotte, NC

### Academic Appointments and Employment

2014-Present **Senior Member**, Biostatistics and Bioinformatics Department, Moffitt Cancer Center, Tampa, Florida

2013-2014 **Senior Member and Interim Chair**, Biostatistics and Biomedical Informatics Department, Moffitt Cancer Center, Tampa, Florida

2008-2013 **Senior Member and Biostatistics Department Chair**, Moffitt Cancer Center, Tampa, Florida

2008-Present **Professor**, Department of Oncologic Sciences, College of Medicine, University of South Florida, Tampa, Florida

2006-Present **Adjunct Professor**, Department of Epidemiology and Biostatistics, University of South Florida, Tampa, Florida

2005-Present **Scientific Director**, Biostatistics Shared Resources, Moffitt Cancer Center, Tampa, Florida

2005-2007 **Professor and Biostatistics Division Chief**, Department of Interdisciplinary Oncology, Moffitt Research Center, Tampa, Florida

2003-2005 **Research Professor**, Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina

1995-2005 **Director of Biostatistics Shared Resource**, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina

1991-2003 **Research Associate Professor**, Department of Biostatistics, University of

North Carolina, Chapel Hill, North Carolina

- 1994-1995     **Director of Biostatistics Shared Resource**, Chao Family Clinical Cancer, University of California, Irvine, California
- 1991-1995     **Associate Professor and Director of Biostatistics**, University of California, Irvine, California
- 1990-1991     **Associate Member**, Division of Biostatistics and Information Systems, St. Jude Children's Research Hospital, Memphis, Tennessee
- 1989-1991     **Adjunct Assistant Professor**, University of Tennessee, Memphis, Tennessee
- 1984-1990     **Assistant Member**, Division of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee

### Teaching Experience

#### **Other Courses and National Symposia**

##### **Short Courses/Lectures**

- March 2018     “Design and Conduct of Clinical Trials”, Translational Biology Course (GMS 6069), USF, 2 hour lecture.
- Spring 2018     BIOS 101 for Moffitt Employees. “Laboratories and Experiments Basics” and Introduction to Clinical Trials”, (Two, 1-hour lecture), Moffitt Cancer Center.
- Spring 2017     BIOS 101 for Moffitt Employees. “Laboratories and Experiments Basics”, (1-hour lecture), Moffitt Cancer Center.
- April 2017     “Statistical Testing” and “Keeping Up with Statistical Practice”, Biostatistics Case Studies and Collaborations I, 3-hour class.
- March 2017     “Design and Conduct of Clinical Trials”, Translational Biology Course (GMS 6069), USF, 2 hour lecture.
- November 2016   “Strategies for Effective Clinical Trial Design and Biostatistics Resources”, Clinical Research Lecture Series (1-hour lecture).
- June 2016       “Colorectal Cancer Mutation Landscape”, SPECS II Conference, Albuquerque, NM, June 29-July 1.
- April 2016       “Statistical Testing” and “Keeping Up with Statistical Practice”, Biostatistics Case Studies and Collaborations I, 3-hour class.
- March 2016       “Design and Conduct of Clinical Trials”, Translational Biology Course (GMS 6069), USF, 2 hour lecture.
- Fall 2015        BIOS 101 for Moffitt Employees. “Laboratories and Experiments Basics” and “Introduction to Clinical Trials”, (Two, 1-hour lectures), Moffitt Cancer Center.

- April 2015 “Statistical Testing” and “Keeping Up with Statistical Practice”, Biostatistics Case Studies and Collaborations I, 3-hour class.
- March 2015 Translation Biotechnology lecture on clinical trials and survival analysis, USF, (2 hours)
- Spring 2015 Bioinformatics 101, “Next-generation sequencing”, (1 hour co-lecture)
- Fall 2014 BIOS 101 for Moffitt Employees. “Laboratories and Experiments Basics” and “Introduction to Clinical Trials”, (Two, 1-hour lectures), Moffitt Cancer Center.
- June 2014 “Classifying Colorectal Cancers Using Targeted Exome Sequencing”, SPECS II Meeting, Boston, MA.
- June 2014 “Statistical Testing” and “Keeping Up with Statistical Practice”, Biostatistics Case Studies and Collaborations I, 3-hour class.
- April 2014 “Introduction to Biostatistics Resources”, Clinical Research Lecture Series, Moffitt Cancer Center.
- October 2013 “Classifying Colorectal Cancers Using Targeted Exome Sequencing”, Biostatistics Journal Club, Moffitt Cancer Center
- August 2013 “Introduction to Next - Gen Sequencing
- June 2013 Direction of Summer Project of 2 undergraduate students for the NHLBI-funded Summer Institute for Training in Biostatistics (SIBS) summer experience in conjunction with Dr. Yiliang Zhu in the department of Epidemiology and Biostatistics at the University of South Florida.
- Spring 2013 BIOS 101 for Moffitt Employees. “Introduction to Biostatistics” and “Clinical Trials”, (Two, 1-hour lectures), Moffitt Cancer Center.
- Spring 2013 “Statistical Testing” and “Keeping Up with Statistical Practice”, Biostatistics Case Studies and Collaborations I, 3-hour class.
- June 2012 Partial Direction of Summer Projects of 9 undergraduate students (3 teams of 3 each) for the NHLBI-funded Summer Institute for Training in Biostatistics (SIBS) summer experience in conjunction with Dr. Yiliang Zhu in the Department of Epidemiology and Biostatistics at the University of South Florida (managed 3-4 30-minute visits per team over a 5-week period)
- Spring 2012 “Statistical Test Decision Making.” School of Public Health, University of South Florida “Biostatistical Case Studies and Collaboration I” 3 hour class.
- Fall 2011 BIOS 101 for Moffitt Employees, “Introduction to Biostatistics” and “Statistical Testing I” Moffitt Cancer Center.

- Spring 2011 “Statistical Test Decision Making.” School of Public Health, University of South Florida “Biostatistical Case Studies and Collaboration I” 3 hour class.
- June 2011 Partial Direction of Summer Projects of 9 undergraduate students (3 teams of 3 each) for the NHLBI-funded Summer Institute for Training in Biostatistics (SIBS) summer experience in conjunction with Dr. Yiliang Zhu in the Department of Epidemiology and Biostatistics at the University of South Florida (managed 3-4 30-minute visits per team over a 5-week period)
- Spring 2011 “Statistical Test Decision Making.” School of Public Health, University of South Florida “Biostatistical Case Studies and Collaboration I” 3 hour class.
- June 2010 Direction of Summer Projects of 10 undergraduate students (2 teams of 5 each) for the NHLBI-funded Summer Institute for Training in Biostatistics (SIBS) summer experience in conjunction with Dr. Yiliang Zhu in the department of Epidemiology and Biostatistics at the University of South Florida (managed 12 3-hour visits per team over a 6-week period)
- Spring 2010 “Statistical Test Decision Making.” School of Public Health, University of South Florida “Biostatistical Case Studies and Collaboration I” 3 hour class.
- Spring 2009 “Statistical Test Decision Making.” School of Public Health, University of South Florida “Biostatistical Case Studies and Collaboration I” 3 hour class.
- Spring, 2009 BIOS 101 for Moffitt Employees, “Introduction to Biostatistics” and “Statistical Testing I” Moffitt Cancer Center.
- Fall 2008 BIOS 101 for Moffitt Fellows, “Introduction to Biostatistics” and “Statistical Testing I” Moffitt Cancer Center.
- Fall 2008 “Statistical Testing Issues.” Moffitt Cancer Biology Ph.D. Graduate Program (one lecture).
- Spring 2008 “Introduction to Biostatistics” Ponce School of Medicine, Puerto Rico
- Fall 2007 “Statistical Testing Issues.” Moffitt Cancer Biology Ph.D. Graduate Program (one lecture).
- Fall 2004 “Statistical Issues in Clinical Trials” for Hematology/Oncology Fellow (2 sessions).
- Fall 2000/  
Fall 2002 “Statistics for Radiation/Oncology Fellows,” (4 sessions), University of North Carolina.
- May 1995 “Clinical Trials: Statistical Issues in Planning and Management,” one-day course, University of California Extension Course.
- May 1994 “Statistics for Scientific Researchers” one-day course, University of California Extension Course.

- Fall 1994 “Statistics for Radiation/Oncology Fellows” (3 of 8 session course),  
University of California, Irvine.
- Fall 1992 “Statistics for Radiation/Oncology Fellows” (3 of 8 session course),  
University of California, Irvine.
- Spring 1989 “Introduction to Biostatistics” (4 of 16 session course), St. Jude Children's  
Research Hospital, Memphis, Tennessee.

**Teaching and Training Experience:**

**Undergraduate training:**

**SPGRE Advisor** (Special Program of Graduate Excellence, a summer internship  
program for the undergraduate minorities.)

- 2003 Roderick Brannan, Choosing the Best Test for the Two-Single Location Problem  
for Small Samples.
- 1998 Brandy Rutledge, A Statistical Analysis of How the Types of p53 mutations  
found in the Carolina Breast Cancer Study compared to those from other studies.
- 1998 Carin Lightner, An Exploration of Phylogenetic Trees in the GAG Gene of  
HIV-1 Nucleotide Sequences.
- 1997 Brandy Rutledge, and Carin Lightner, A Statistical Analysis of Amino Acid and  
Codon Usage in Organisms.

**Graduate training:**

**Master Thesis Advisor**

- 2003 Binbin Zhang, Two-Sample Location Problem with Small Samples: Power  
Comparison of Parametric and Non-Parametric Tests, UNC-Chapel Hill,  
Biostatistics.
- 2002 Fang Gai, James-Stein Estimation, UNC-Chapel Hill, Biostatistics.
- 2001 Daniel Scharf, Matrix Order Reduced Isotonic and Reduced Monotonic  
Regression, UNC-Chapel Hill, Biostatistics, 2001. (Won award as one of Best  
Master’s Papers of 2001.)
- 2000 Trang Lance, Early Analytic Evaluation of Practice and Radiologist Variation in  
the Density Assessment of Screening Mammograms, UNC-Chapel Hill,  
Biostatistics.
- 1997 Shibing Deng, Computation and Studies on Maximally Selected Chi-Square  
Statistics, Biostatistics, UNC-Chapel Hill, 1997. (Won award as Best Master’s  
Paper of 1997.)
- 1997 Sean O’Brien, Optimal Grouping Strategies for Categorizing Continuous Explanatory  
Variables, UNC-Chapel Hill, Biostatistics.
- 1997 Stefanie Silva, Comparison of Ischemic Pain Intensity Ratings on TMD and  
Control Populations: A Mixed Model Analysis of Longitudinal Data, UNC-  
Chapel Hill, Biostatistics.

### **Master Thesis Committee**

2001 Ahinee Amamoo, UNC-Chapel Hill, Biostatistics  
1997 Pamela Sue LaDuke, UNC-Chapel Hill, Biostatistics  
1995 Craig Uejo, San Diego State University, Public Health

### **Doctoral Field Experience**

2014-15 Muditha Perera, Dept. of Mathematics and Statistics, USF

### **Master Field Experience**

2015 Mentor for Ms. Mahrukh Naqvi, Dept. of Epidemiology and Biostatistics, USF  
2010 Mentor for Mr. Yong Xu, Graduate Teaching Assistant, Dept. of Statistics, USF  
2010 Mentor for Mr. Zhengming Chen, Dept. of Epidemiology and Biostatistics, USF  
2006 Mentor for Mr. Xiaowu Zhou, Dept. of Epidemiology and Biostatistics, USF

### **Doctoral Committee**

2003 Kai Wang, UNC-Chapel Hill, Biostatistics  
2003 Ji-Hyun Lee, UNC-Chapel Hill, Biostatistics  
2003 Lynette Phillips, UNC-Chapel Hill, Epidemiology  
2003 Brian Neelon, UNC-Chapel Hill, Biostatistics  
2002 Sean O'Brien, UNC-Chapel Hill, Biostatistics  
2000 Michael Cassell, UNC-Chapel Hill, Health Behavior Health Education  
2000 Joe Galanko, UNC-Chapel Hill, Biostatistics  
2000 Lynne Wilkens, UNC-Chapel Hill, Biostatistics  
1999 Eric Duell, UNC-Chapel Hill, Epidemiology  
1998 Wen-Yi Huang, UNC-Chapel Hill, Epidemiology  
1998 Susan Hastings, UNC-Chapel Hill, Nutrition  
1998 Dina Schreinemachers, UNC-Chapel Hill, Biostatistics  
1997 Zuzana Bic, Loma Linda University, Preventive Care & Epidemiology

### **Graduate Research Assistanceships**

2004– 2005 Laura Lapkauskaite  
2003 – 2005 Jaeun Choi  
2003 – 2005 Yeonseong Chung  
2002 Yanfang Zhiang (Information Science)  
2001 – 2003 Liyun Ni  
2000 – 2001 Yun Li  
2000 – 2003 Ji-Hyun Lee  
2000 – 2003 Jackie Johnson  
1998 – 2000 Shen Zhuang  
1998 – 2000 Ahinee Amamoo  
1997 – 2003 Brian Nelson

1996            Shibing Deng  
1995 – 2002    Sean O'Brien

**Full-Time Staff Statisticians Under Supervision**

Moffitt Cancer Center and Research Institute, University of South Florida

2016 – Present Junmin Zhou  
2016 – 2017    Braydon Schaible  
2015 – Present Jiannong Li  
2015 – Present Mahrukh Naqvi  
2015 – Present Ram Thapa  
2015 – 2016    Nelson Torres  
2014 – 2015    Tzu-Hua Juan  
2011 – 2015    Binglin Yue  
2011 – 2015    Kate Fisher  
2009 – 2011    Gang Han  
2009 – 2010    Lulu Yan  
2008 – 2011    Bhupendra Rawal  
2008 – 2015    Xiuhua Zhao  
2007 – 2015    Jimmy Fulp  
2006 – 2007    Gui Gao  
2005 – 2008    Rachna Kapoor  
2005 – 2008    David Boulware

Lineberger Comprehensive Cancer Center, University of North Carolina

2004 – 2005    Li Lin  
1999 – 2005    Dominic Moore  
1997 – 1998    Ahinee Amamoo  
1997 – 1998    Sean O'Brien  
1996 – 2001    Yuhua Lin

**Honors and Awards**

B.S. and B.A. degrees earned magna cum laude

A.K. Anderson award at the University of North Carolina, Charlotte, NC in 1979 (top graduating mathematics student)

Teaching Fellowship at Florida State University, Tallahassee, FL 1979-80

University Fellowship at Florida State University, Tallahassee, FL 1983-84

Delta Omega, Theta Chapter, 1999

Outstanding Faculty Performance Award, Population Science Division, Moffitt Cancer Center & Research Institute, 2014

Faculty Statistician of the Year, Biostatistics Core, 2017

**Research Support**

**Current**

**External Grants**

Account:  
Name of PI: **(Heine)**  
Dates: 04/01/2019 – 03/21/2022  
Funding Source: State of Florida—Bankhead Coley  
Title: Understanding breast structure with Deep Learning  
% Effort: 3%  
Role in the study: Co-Investigator  
Total Direct Costs: \$781,862  
Total Amount of Award: \$117,279  
Date Submitted: October 2018

Account:  
Name of PI: **(Shain/Silva)**  
Dates: 07/25/2018 – 06/30/2020  
Funding Source: Multiple Myeloma Research Foundation  
Title: Big data and machine learning to inform care pathways on the use of maintenance therapy in multiple myeloma  
% Effort: 10%  
Role in the study: Co-Investigator  
Total Direct Costs: \$453,888  
Total Amount of Award: \$998,554  
Date Submitted: March 2018

Account:  
Name of PIs: **(Giuliano)**  
Dates: 08/01/2017 – 09/30/2018  
Source: Merck & Co., Inc.  
Title: The Role of Genital Warts in HIV Acquisition among Men Participating in a Longitudinal Study from the United States, Brazil and Mexico  
% Effort: 5%  
Role in the Study: Co-Investigator  
Total Direct Costs: \$319,808  
Total Amount of Award: \$415,750

Account: 5 R01 CA214588  
Name of PI: **(Giuliano)**  
Dates: 04/01/2017 – 03/31/2022  
Funding Source: NIH/NCI  
Title: Investigation of Oral HPV Infection Natural History and Biomarkers of Persistent Infection- The HIM Study  
% Effort: 4%  
Role in the study: Co-Investigator  
Total Direct Costs: \$2,492,625  
Total Amount of Award: \$4,277,635



Account: 1U48DP005024-01  
Name of PI: **(Baldwin/ Gwede)**  
Dates: 09/30/2014 – 09/29/2019  
Source: CDC  
Title: Community Based Prevention Marketing for Systems Change:  
Reducing Disparities  
Effort: 2%  
Role in the Study: Co-Investigator/Biostatistician  
Total Direct Costs: \$49,074 USF main= \$615,229  
Total Amount of Award: \$73,366 USF Main =\$750,000

Account: 5 R01 CA177586  
Name of PI: **(Rollison)**  
Dates: 04/02/2014 – 02/28/2019  
Source: NIH/NCI  
Title: Prospective Study of Cutaneous Viral Infections and Non-  
Melanoma Skin Cancer  
% Effort: 6%  
Role in the Study: Co-Investigator  
Total Direct Costs: \$1,994,194  
Total Amount of Award: \$3,354,636

Account: 5P30CA07692  
Name of PI: **(Sellers)**  
Dates: 02/01/12 – 01/31/2022  
Source: NIH/NCI  
Title: H. Lee Moffitt Cancer Center and Research Institute Support  
Grant  
% Effort: 10%  
Role in the Study: Biostatistics Core Principal Investigator  
Total Direct Cost: \$7,825,195  
Total Amount of Award: \$13,459,335

Account: 8JK03  
Name of PI: **(Kumar)**  
Dates: 05/03/2018 – 03/31/2023  
Funding Source: State of Florida/ JEK  
Title: Chemoprevention of Lung Cancer in Former Smokers  
% Effort: 3%  
Role in the study: Co-Investigator  
Total Direct Costs: \$265,000  
Total Amount of Award: \$1,325,000

### **Pending**

#### **External Grants**

Account:

Name of PI: **(Vadaparampil/Christy)**  
Dates: 04/01/2019 – 03/31/2024  
Funding Source: State of Florida- JEK  
Title: HPV PRACTICE: Promoting Rates of Acceptance and Completion with Technology, Intervention, Communication, and Education  
% Effort: 5%  
Role in the study: Co-Investigator  
Total Direct Costs: \$1,279,778  
Total Amount of Award: \$1,471,746  
Date Submitted: November 2

Account:  
Name of PI: **(Meade/Gwede)**  
Dates: 04/01/2019 – 03/31/2023  
Funding Source: State of Florida- Bankhead Coley  
Title: CARES-REACH (Colorectal Cancer Awareness, Research, Education and Screening-Rural Expansion, Access and Capacity for Health  
% Effort: 5%  
Role in the study: Co-Investigator  
Total Direct Costs: \$1,304,347  
Total Amount of Award: \$1,499,999  
Date Submitted: November 2018

Account:  
Name of PI: **(Kumar)**  
Dates: 04/01/2019 – 03/31/2024  
Funding Source: State of Florida- Bankhead Coley  
Title: Phase II Clinical Trial of GTC in Men on Active Surveillance  
% Effort: 10%  
Role in the study: Co-Investigator  
Total Direct Costs: \$1,307,125  
Total Amount of Award: \$192,870  
Date Submitted: March 2018

Account:  
Name of PI: **(Kumar)**  
Dates: 07/01/2019 – 06/30/2024  
Funding Source: NIH/NCI  
Title: Phase II Clinical Trial of Green Tea Catechin in Men on Active Surveillance  
% Effort: 10%  
Role in the study: Co-Investigator  
Total Direct Costs: \$2,350,435  
Total Amount of Award: \$3,883,016  
Date Submitted: November 2018

Account:

Name of PI: **(Heine)**  
Dates: 07/01/2019 – 06/30/2023  
Funding Source: NIH  
Title: Understanding the Structure of Mammograms with Deep Learning  
% Effort: 10%  
Role in the study: Co-Investigator  
Total Direct Costs: \$ 1,825,302  
Total Amount of Award: \$ 3,134,849

Account: R01 CA227529-01  
Name of PI: **(Kumar)**  
Dates: 04/01/2019 – 03/31/2024  
Funding Source: NIH  
Title: (PQ11) Phase II Clinical trial valuating the safety, effectiveness and mechanism by which a Ketogenic Diet reduces biomarkers od disease progression in patients diagnosed with low grade gliomas  
% Effort: 10% (resubmission)  
Role in the study: Co-Investigator  
Total Direct Costs: \$ 2,306,717  
Total Amount of Award: \$ 3,792,782

Account:  
Name of PI: **(Kumar)**  
Dates: 04/01/2019 – 03/31/2023  
Funding Source: NIH  
Title: A Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention  
% Effort: 10%  
Role in the study: Co-Investigator  
Total Direct Costs: \$ 1,562,141  
Total Amount of Award: \$ 2,599,596

Account:  
Name of PI: **(Kumar)**  
Dates: 01/01/2019 – 12/31/2023  
Funding Source: NIH  
Title: A phase II clinical trial of levothyroxine in ameliorating symptoms of fatighe and other symptoms cluster in Breast cancer survivors  
% Effort: 10%  
Role in the study: Co-Investigator  
Total Direct Costs: \$ 2,123,916  
Total Amount of Award: \$ 3,250,468

Account: R01  
Name of PI: **(Kumar)**  
Dates: 09/01/2018 – 08/31/2022  
Funding Source: NIH

Title: Phase II Clinical Trial of GTC in Men on Active Surveillance  
% Effort: 10%  
Role in the study: Co-Investigator  
Total Direct Costs: \$1,682,112  
Total Amount of Award: \$2,865,648  
Date Submitted: March 2018

**Completed**

**External Grants:**

Account: 5R01HL114994  
Name of PI: **(Anasetti)**  
Dates: 08/01/13 – 04/30/18  
Source: NIH/NHLBI  
Title: Adoptive Transfer of Donor Tregs Specific Against Host Alloantigens for Prevention of Human GVHD  
% Effort: 5%  
Role in the Study: Co-Investigator  
Total Direct Costs: \$277,904  
Total Amount of Award: \$468,268

Account: 4P50CA168536  
Name of PI: **(Sondak)**  
Dates: 09/20/13 – 07/31/18  
Source: NIH/NCI  
Title: Moffitt Skin Cancer SPORE  
% Effort: 15%  
Role in the Study: Co-Director, Core B  
Total Direct Costs: \$6,641,749  
Total Amount of Award: \$10,149,665

Account: 02-60000-18-01  
Name of PIs: **(Kumar)**  
Dates: 07/01/2017-06/30/2018  
Source: State of Florida/ MCC  
Title: Medical Marijuana Research and Education  
% Effort: 7% effective 03/01/2018 through 06/30/2018  
Role in the Study: Biostatistician  
Total Direct Costs: \$648,968  
Total Amount of Award: \$746,313

Account: 54974  
Name of PIs: **(Giuliano)**  
Dates: 08/01/2017 – 02/28/2018  
Source: Merck & Co., Inc.  
Title: Oral HPV Antibody Kinetics and Function Post-Vaccination among HIV- and HIV + Men  
% Effort: 3%  
Role in the Study: Co-Investigator  
Total Direct Costs: \$198,805

Total Amount of Award: \$150,000

Account: 4U01CA157960-05  
Name of PI: **(Yeatman; Schell, Moffitt PI)**  
Dates: 09/19/12 – 08/31/17  
Source: NIH / NCI  
Title: Individualizing Colon Cancer Therapy Using Hybrid RNA and DNA Molecular Signature  
% Effort: 9%  
Role in the Study: Co-Investigator  
Total Direct Costs: \$1,915,278  
Total Amount of Award: \$2,560,539

Account: 5R01CA160104-05  
Name of PI: **(Craig)**  
Dates: 09/09/11 – 07/31/16 (Effort completed 04/07/2016)  
Source: NIH/NCI  
Title: HRQoL Values For Cancer Survivors: Enhancing PROMIS Measures for CER  
% Effort: 6%  
Role in the Study: Biostatistician Co-Investigator  
Total Direct Costs: \$2,091,804  
Total Amount of Award: \$3,129,188

Account: Pending  
Name of PI: **(Mulé)**  
Source: Sullivan Fund  
Dates: 11/21/2013 – 11/20/2016 (Effort completed 10/01/2015)  
Title: “Project 3 – Improving Patient Survival”  
% Effort: 10%  
Role: Co-Investigator  
Total Direct Costs: \$1,400,001  
Total Amount of Award: \$1,400,001

Account: 5P50CA119997-05  
Name of PI: **(Haura)**  
Dates: 09/15/08 – 08/31/14 (NCE status)  
Source: NIH  
Title: SPORE in Lung Cancer  
% Effort: 15% years 1-4, 10% year 5, 5% during NCE  
Role in the Study: Statistical Co-investigator  
Total Direct Cost: \$6,099,694  
Total Amount of Award: \$10,000,000

Account: 5R01CA122060-05  
Name of PI: **(Kumar)**  
Dates: 07/01/07 – 05/31/14  
Source: NIH/NCI  
Title: A Phase II Clinical trial of Polyphenon E in Prostrate Cancer  
% Effort: 2.5% (Effort completed 01/2014)  
Role in the Study: Co-Investigator

Total Direct Costs: \$ 2,304,660.85  
Total Amount of Award: \$ 3,544,690

Account: 9R01CA132197-06A2  
Name of PI: **(Anasetti)**  
Dates: 08/25/08 – 07/31/13  
Source: NIH  
Title: Antigen Specific T Cell Tolerance by Anti CD3 Antibodies  
% Effort: 5%  
Role in the Study: Statistical Co-investigator  
Total Direct Costs: \$1,105,067  
Total Amount of Award: \$1,843,468

Account: 1R01 CA131080-01A2  
Name of PI: **(Lengacher/Schell)**  
Dates: 02/01/09 – 6/30/13  
Source: USF  
Title: MBSR Symptom Cluster Trial for Breast Cancer Survivors  
% Effort: 2%  
Role in the Study: Statistical co-investigator  
Total Direct Costs: \$25,213  
Total Amount of Award: \$223,295

Account: 1R01CA122060-01A1  
Name of PI: **(Kumar)**  
Dates: 07/01/08 – 05/31/13  
Source: NIH  
Title: Phase II Clinical Trial of Polyphenon E in Prostate Cancer  
% Effort: 5% (downshifted to 2.5% during extension)  
Role: Statistical co-investigator  
Total Direct Costs: \$569,244  
Total Amount of Award: \$700,250

Account: R01 CA129343  
Name of PI: **(Bepler)**  
Dates: 04/01/08 – 01/31/2013  
Source: NIH/NCI  
Title: RRM1 in the Management of Lung Cancer  
% Effort: 5%  
Role: Statistical co-investigator  
Total Direct Costs: \$379,321  
Total Amount of Award: \$3,470,614

Account: 5R01CA121182-04  
Name of PI: **(Haura)**  
Dates: 3/1/07 – 1/31/12  
Source: NIH  
Title: Stat3 in EGFR Driven Non-Small Cell Lung Cancer  
% Effort: 3%  
Role: Statistical Co-investigator  
Total Direct Costs: \$175,000

Total Amount of Award: \$ N/A

Account: 5P30CA07692-13  
Name of PI: **(Dalton)**  
Dates: 2/1/07 – 1/31/12  
Source: NIH/NCI  
Title: Moffitt Cancer Center and Research Institute Support Grant  
% Effort: 11%  
Role in the Study: Biostatistics Core PI  
Total Direct Costs: \$8,253,224  
Total Amount of Award: \$13,641,447

Account: 1RC2 CA148322-01  
Name of PI: **(Fenstermacher)**  
Dates: 09/29/09 – 08/31/11  
Source: NIH/NCI (ARRA)  
Title: Developing Information Infrastructure Focused on Cancer Comparative Effectiveness  
% Effort: 10%  
Role in the Study: Statistical co-investigator  
Total Direct Costs: \$604,780  
Total Amount of Award: \$ N/A

Account: 84-15941-01-01  
Dates: 06/01/10 – 05/1/2011  
Source: EUSA Pharma (USA), Inc  
Title: Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer  
% Effort: 2%  
Role in the Study: Statistical Advisor  
Total Direct Costs: \$37,125  
Total Amount of Award: \$51,975

Account: 07BR-02  
Name of PI: **(Sondak)**  
Dates: 7/1/07 – 6/30/10  
Source: FL Dept. of Health  
Title: Melanoma SPORE Planning Grant  
Role: Statistical co-investigator  
Total Direct Cost: \$286,881  
Total Amount of Award: \$ N/A

Account: R01 30-15775-99-01  
Name of PI: **(Monteiro)**  
Dates: 07/01/09 – 06/30/10  
Source: NIH/NCI  
Title: BRACA-1 Status as a Marker of Clinical Outcome in Lung Cancer  
% Effort: 3%  
Role in the Study: Statistical co-investigator  
Total Direct Costs: \$200,000

Total Amount of Award: \$ N/A

Account: 69-15075-99-01  
Name of PI: **(Haura)**  
Dates: 7/1/07 – 6/30/10  
Source: ASCO  
Title: Targeting EGFR and SRC in Tyrosine Kinase Signaling in Lung Cancer  
% Effort: 0.5%  
Role in the Study: Biostatistics Core PI  
Total Direct Costs: \$414,461  
Total Amount of Award: \$ N/A

Account: R01 CA 105139-01A2  
Name of PI: **(Weber)**  
Dates: 07/01/08 – 05/31/10  
Source: NIH/NCI  
Title: Dendritic cell vaccination during lymphoid reconstitution  
% Effort: 20%  
Role: Statistical co-investigator  
Total Direct Cost: \$384,637  
Total Amount of Award: \$ N/A

Account: 7R01 CA109307  
Name of PI: **(Weber)**  
Dates: 09/01/04 – 08/31/09  
Source: NCI  
Title: CTLA-4 Inhibition and Autoimmunity in Melanoma  
% Effort: 4%  
Role: Statistical co-investigator  
Total Direct Cost: \$870,431  
Total Amount of Award: \$ N/A

Account: 10-15073-99-01  
Name of PI: **(Haura)**  
Dates: 06/01/07 – 04/30/09  
Source: NIH  
Title: Antitumor Mechanisms of SRC  
% Effort: 5%  
Role: Statistical co-investigator  
Total Direct Costs: \$1,265,083  
Total Amount of Award: \$

Account: U01 CA101222-01  
Name of PI: **(Bepler)**  
Dates: 09/15/03 – 08/31/08  
Source: NCI  
Title: Exisulind for Chemoprevention of Lung Cancer  
% Effort: 5%  
Role: Statistical co-investigator  
Total Direct Costs: \$3,089,222



Total Amount of Award: \$5,035,433

Account: 1R01 CA 133594  
Name of PI: **(Djulbegovic)**  
Dates: 05/28/07 – 07/31/08  
Source: DOC  
Title: Quality of Research on Treatment Harms in Cancer  
% Effort: 3%  
Role in the Study: Statistical co-investigator  
Total Direct Costs: \$285,250  
Total Amount of Award: \$570,500

Account: R01 CA10272-0101  
Name of PI: **(Bepler)**  
Dates: 07/01/03 – 06/30/08  
Source: NIH  
Title: RRM1/PTEN Axis in Response and Survival of Non-Small Cell Lung Cancer  
% Effort: 5%  
Role: Statistical co-investigator.  
Total Direct Costs: \$1,719,855  
Total Amount of Award: \$2,518,983

Account: G1500Z8 (94-14103-99-01)  
Name of PI: **(Anasetti)**  
Dates: 04/03/07 – 04/02/08  
Source: Pfizer, Inc.  
Title: A Retrospective Comparison of Fluconazole with Voriconazole as Fungal Prophylaxis in a Bone Marrow Transplant  
% Effort: 0.5%  
Role in the Study: Biostatistics Core PI  
Total Direct Costs: \$80,000  
Total Amount of Award: \$ N/A

Account: 6302036L0  
Name of PI: **(Djulbegovic)**  
Dates: 09/01/05 – 07/31/07  
Source: NIH  
Title: Evaluation of the Quality of Clinical Trials  
% Effort: 1%  
Role: Statistical co-investigator  
Total Direct Costs: \$350,000  
Total Amount of Award: \$450,000

Account: R21 CA110487-01A1  
Name of PI: **(Bepler)**  
Dates: 04/01/05 – 03/31/07  
Source: NCI  
Title: Pharmacogenomics of Neoadjuvant Gemcitabine-Pemetrexed  
% Effort: 5%  
Role: Statistical co-investigator

Total Direct Costs: \$385,718  
Total Amount of Award: \$573,746  
  
Account: R21 CA106166-01  
Name of PI: **(G. Simon)**  
Dates: 06/30/06 – 09/07/06  
Source: NCI  
Title: Molecular Analysis-Directed Individualized Therapy in  
Advanced Non-Small Cell Lung Cancer  
  
% Effort: 3%  
Role in the Study: Statistical co-investigator  
Total Direct Costs: \$N/A  
Total Amount of Award: \$N/A

Account: P01 CA82533 04  
Name of PI: **(Sullivan)**  
Dates: 05/01/00 – 04/01/06  
Source: NCI  
Title: MOPP-Clinical Trial Core  
% Effort: 5%  
Role in the Study: Head of Biostatistics Core  
Total Direct Costs: \$1,056,312  
Total Amount of Award: \$1,119,815

**Completed (Cont.)**

**Internal Grants:**

Account: N/A  
Name of PIs: **(Giuliano/Vadaparampil)**  
Dates: 01/01/2017 – 01/31/2018  
Source: Moffitt Cancer Center, Team Science  
Title: Reversing the Hepatocellular Carcinoma Trends in Moffitt's  
Catchment Areas: HVC Screening  
  
% Effort: 9%  
Role in the Study: Co-Investigator  
Total Direct Costs: \$150,000  
Total Amount of Award: \$150,000

Account: n/a  
Name of PI: **(Rollison & Burnette)**  
Dates: 11/05/2015 – 02/04/2017  
Source: Moffitt Cancer Center, Team Science  
Title: Immunosuppressive T-cells and Keratinocyte Cancer  
% Effort: 2%  
Role in the Study: Co-Investigator  
Total Direct Costs: \$50,000  
Total Amount of Award: \$50,000  
Effort ended: 2/25/2017

Account: n/a  
Name of PI: **(Giuliano)**

Dates: 07/01/2015 – 09/30/2016  
Source: Moffitt Cancer Center, Miles for Moffitt  
Title: Oral Immunological Response to HPV Vaccine: Extending the  
Cancer Prevention Benefits of Vaccination  
% Effort: 3%  
Role in the Study: Co-Investigator  
Total Direct Costs: \$100,000  
Total Amount of Award: \$100,000

Account: n/a  
Name of PI: **(Djeu, Brandon & Wei)**  
Dates: 07/30/2015 – 07/29/2016  
Source: Moffitt Cancer Center, Team Science  
Title: The Role of microRNA-183 in Natural Killer Cell Function  
against Human Lung Cancer  
% Effort: 1%  
Role in the Study: Co-Investigator  
Total Direct Costs: \$118,718  
Total Amount of Award: \$118,718

### University of North Carolina at Chapel Hill (1995-2005)

#### External Grants:

Account: 2-U01-CA70040  
Name of PI: **(Yankaskas) (Schell Co-PI)**  
Dates: 10/1/00 – 7/3/05  
Source: NCI  
Title: Breast Cancer Surveillance Research in North Carolina, Part I  
% Effort: 5%  
Total Direct Costs: \$483,652.00

Account: 1 U01-CA70040-06  
Name of PI: **(Yankaskas)**  
Dates: 10/1/00 – 07/31/05  
Source: NCI  
Title: Breast Cancer Surveillance Research in North Carolina, Part II  
% Effort: 10%  
Role in the Study: Statistical co-director of this project  
Total Direct Costs: \$33,106.00

Account: 5-P50-CA58223 (Earp, III)  
Dates: 8/1/01 – 7/31/06  
Source: NCI  
Title: SPOR in Breast Cancer - Core 4: Biostatistics and  
Bioinformatics Core  
% Effort: 10%  
Role in the Study: Director of Core 4  
Total Direct Costs: \$33,106.00

Account: DAMD17-03-2-0052

Name of PI: **(Mohler)**  
Dates: 9/1/03 – 8/31/06  
Source: U.S. Army Medical Research  
Title: Racial Differences in Prostate Cancer: Influence of Health Care and Host and Tumor Biology, Core 1 - Epidemiology  
% Effort: 15%  
Role in the Study: Statistical co-director of this project  
Total Direct Costs: \$828,010.00

Account: Not assigned  
Name of PI: **(Baucom)**  
Dates: 4/1/04 – 3/31/09  
Source: NCI  
Title: A Couples Approach to Enhance Breast Cancer Survivorship  
% Effort: 10%  
Role in the Study: Statistical co-investigator  
Total Direct Costs: \$494,489.00

Account: P30-CA16086-31  
Name of PI: **(Earp, III)**  
Dates: 12/1/04 – 11/30/09  
Source: NCI  
Title: Cancer Center Core Support Grant-Biostatistics and Data Management Core  
% Effort: 30%  
Role in the Study: Director of Biostatistics and Data Management Core  
Total Direct Costs: \$390,991.00

Account: 5-P30-CA16086-26  
Name of PI: **(Earp, III)**  
Dates: 12/01/99 – 11/30/04  
Source: NCI  
Title: Cancer Center Core Support Grant- Biostatistics and Data Management Core  
% Effort: 30%  
Role in the Study: Director of the Core  
Total Direct Costs: \$273,763

Account: Not Available  
Name of PI: **(Serody)**  
Dates: 12/01/01 – 11/30/06  
Source: NIH  
Title: Enhancing DC-based Immunotherapy for Breast Cancer, Clinical Component  
% Effort: 5%  
Role in the Study: Statistical co-investigator  
Total Direct Costs: \$254,004

Account: 1 R01-CA65910

Name of PI: **(Cance)**  
Dates: 7/01/00 – 6/30/04  
Source: NIH  
Title: Focal Adhesion Kinase Tumor Biology and Therapeutics  
% Effort: 5%  
Role in the Study: Statistical co-investigator  
Total Direct Costs: \$221,484

Account: 1-P01-CA77739-02  
Name of PI: **(Mohler)**  
Dates: 7/01/99 – 6/30/03  
Source: NCI  
Title: Prostate Cancer: Transition to Androgen Independence, Proj 1  
Androgen Receptor Function in Prostate Cancer  
% Effort: 5%  
Role in the Study: Statistical co-investigator  
Total Direct Costs: \$250,553

Account: 1-P01-CA77739-02  
Name of PI: **(Mohler)**  
Dates: 7/01/99 – 6/30/03  
Source: NCI  
Title: Prostate Cancer: Transition to Androgen Independence, Proj 2  
Androgen Receptor Function in Recurrent Prostate Cancer  
% Effort: 2.5%  
Role in the Study: Statistical co-investigator  
Total Direct Costs: \$237,663

Account: 1-P01-CA77739-02  
Name of PI: **(Mohler)**  
Dates: 7/01/99 – 6/30/03  
Source: NCI  
Title: Prostate Cancer: Transition to Androgen Independence, Core B  
Immunoanalysis  
% Effort: 2.5%  
Role in the Study: Statistical co-investigator  
Total Direct Costs: \$181,003

Account: LCCC 9719  
Name of PI: **(Socinski)**  
Dates: 1/14/98 – 1/13/03  
Source: Bristol-Meyers Squibb  
Title: Phase III Randomized Trial Comparing a Defined Duration  
Versus Continuous Administration of Combination  
% Effort: 5%  
Role in the Study: Statistical co-investigator  
Total Direct Costs: \$148,483

Account: TPRH-99-254-01-CCE

Name of PI: **(Godley)**  
Dates: 5/01/99 – 4/30/02  
Source: American Cancer Society  
Title: A Case-Control Study of Prostate Cancer Screening  
% Effort: 5%  
Role in the Study: Statistical co-investigator  
Total Direct Costs: \$289,000

Account: 00868-02  
Name of PI: **(Pisano)**  
Dates: 8/15/00 – 8/14/02  
Source: NC Department of Health and Human Services  
Title: Mammography Quality Assurance  
% Effort: 2%  
Role in the Study: Statistical co-investigator  
Total Direct Costs: \$84,636

Account: 1-P30-DK56350-01  
Name of PI: **(Zeisel)**  
Dates: 9/30/99 – 9/29/04  
Source: National Inst. of Health  
Title: Clinical Nutrition Research Unit Core Grant  
% Effort: 7.5%  
Role: Director of the Core, 1999-2000  
Total Direct Costs: \$932,723

Account: 1-R21-CA89961-01  
Name of PI: **(Serody)**  
Dates: 9/30/00 – 9/29/01  
Source: National Cancer Institute  
Title: Immunotherapy for Metastatic Breast Cancer  
% Effort: 5%  
Role: Statistical co-investigator  
Total Direct Costs: \$180,000

Account: LCCC9904  
Name of PI: **(Collichio)**  
Dates: 12/01/99 – 7/31/01  
Source: Roche Pharmaceuticals  
Title: XEL023 - A Phase I/II Trial of Xeloda, Every 3 Week Taxol,  
and Herceptin in Metastatic Breast Cancer  
% Effort: 1.25%  
Role: Statistical co-investigator  
Total Direct Costs: \$30,000

Account: 00073-99  
Name of PI: **(Campbell)**  
Dates: 10/01/98 – 9/30/00  
Source: US Depart. of Agriculture  
Title: Colorectal Cancer Prevention in Rural Black Churches  
% Effort: 5%

Role: Statistical co-investigator  
Total Direct Costs: \$142,730

Account: N01-CN-75035-70  
Name of PI: **(Zeisel)**  
Dates: 6/01/98 – 9/29/00  
Source: National Cancer Institute  
Title: Phase I single & multiple-dose safety pharmacokinetic, in women – isoflavone mixtures

% Effort: 10%  
Role: Statistical co-investigator  
Total Direct Costs: \$860,000

Account: RPG-97-110-01-CCE  
Name of PI: **(Dorsey)**  
Dates: 7/01/97 – 6/30/01  
Source: American Cancer Society  
% Effort: 2%  
Title: p53 Alterations in Benign Breast Lesions and Development of Breast Cancer

Role: Statistical co-investigator  
Total Direct Costs: \$80,000

Account: LCCC9727  
Name of PI: **(Shea)**  
Dates: 10/31/97 – 9/30/00  
Source: AMGEN Inc.  
Title: Multiple cycles of high dose chemotherapy supported with Filgrastim and peripheral blood cells in patients with metastatic breast cancer.

% Effort: 5%  
Role: Statistical co-investigator  
Total Direct Costs: \$105,000

Account: LCCC 9611  
Name of PI: **(Socinski)**  
Dates: 7/01/97 – 6/30/98  
Source: Glaxo-Wellcome  
Title: Evaluation of oral antiemetic regimens for moderately high to highly emetogenic chemotherapy: pilot study of

% Effort: 0%  
Role: Statistical co-investigator  
Total Direct Costs: \$240,000

Account: 1-P50-CA58223-08  
Name of PI: **(Earp, III)**  
Dates: 9/30/95 – 7/31/01  
Source: National Cancer Institute  
Title: SPORE in Breast Cancer - Data Management Core  
% Effort: 10%  
Role: Statistical co-investigator

Total Direct cost: \$79,693

Account: 1-U01-CA70040-05  
Name of PI: **(Yankaskas)**  
Dates: 9/30/95 – 7/31/00  
Source: National Cancer Institute  
Title: Breast Cancer Surveillance Research in North Carolina -  
Subcontract

% Effort: 10%  
Role: Statistical co-investigator  
Total Direct Costs: \$367,670

Account: SuperGen  
Name of PI: **(Mohler)**  
Dates: 3/15/98 – 7/15/99  
Title: Project 1: The toxicity and efficacy of Coumarin versus  
advanced kidney and prostate cancer

% Effort: 5%  
Role: Statistical co-investigator  
Total Direct costs: \$109,010

Account: DAMD17-94-J-4334  
Name of PI: **(Yankaskas)**  
Dates: 9/30/94 – 9/29/98  
Source: U.S. Army Medical Research  
Title: Population-Based Mammography Registry

% Effort: 5%  
Role: Statistical co-investigator  
Total Direct Costs: \$257,860

### **University of California at Irvine (1991-1995)**

Account:  
Name of PI: **(P. Luce-Aoelua)**  
Dates: 7/01/94 – 6/30/97  
Source: National Cancer Institute  
Title: Cancer Control Needs Among American Samoans

% Effort: 10%  
Role: Statistical co-investigator  
Total Cost: \$1,471,048

Account: CA-50364  
Name of PI: **(M. Berman)**  
Dates: 9/30/91 – 8/31/96  
Source: National Cancer Institute  
Title: Chemoprevention of Cervical Cancer with Beta-Carotene

% Effort: 15%  
Role: Statistical co-investigator  
Total Cost: \$1,468,509

Account: NCI P30



Name of PI: **(F. Meyskens)**  
Dates: 2/01/94 – 1/31/97  
Source: National Cancer Institute  
Title: Center Grant for UCI Cancer Center  
% Effort: 50%  
Role: Biostatistics Shared Resource Director/Statistical co-investigator  
Total Cost: \$3,174,323

**St. Jude Children's Research Hospital, Memphis TN (1984-1991)**

- 1) National Cancer Institute Cancer Center Support Grant
- 2) National Cancer Institute Leukemia Program Project Grant (CA20181)
- 3) National Cancer Institute Solid Tumor Program Project Grant

**Dissertation**

**Schell MJ.** An increasing failure rate approach to low dose extrapolation.

**Service**

**Moffitt Cancer and Research Center**

**1. Administrative Appointments:**

2005 – Present Director, Biostatistics Shared Resource, H. Lee Moffitt Cancer Center.  
2013-2014 Interim Chair, Biostatistics and Bioinformatics Department

**2. Committees:**

2016-present Biostatistics Core Committee (ex officio)  
2015-2016 Behavioral Scientific Review Committee  
2014 – present Biostatistics and Bioinformatics Department Executive Committee  
2014 – present Core Leadership Committee  
2013 – 2015 TCC Faculty Advisory Committee  
2012 – 2014 Biomarker Validation Committee  
2012 – 2014 Personalized Clinical Trials Committee  
2011 – 2013 TCC Data Standards & Release Committee  
2011 – 2012 Laurel Board Scientific Review Committee  
2010 – present Protocol Monitoring Committee  
2010 – 2015 Scientific Review Committee (backup member)  
Fall 2008 – 2014 Research Institute Steering Committee (RISC)  
Fall 2007 – 2010 Data Quality Executive Committee  
Fall 2007 – 2010 Database Stakeholders Committee  
12/05 – 2014 Population Science Executive Committee  
12/05 – 2014 Scientific Leadership Committee  
12/05 – 2014 Bioinformatics Steering Committee  
02/06 – 10/06 Protocol Monitoring Committee  
12/05 – 9/06 Protocol Review and Monitoring Committee Magnolia  
12/05 – 9/06 Scientific Review Committee

12/05 – 4/06 Protocol Review and Monitoring Committee Holly  
12/05 – 6/06 Total Cancer Care Data Committee

### **3. Internal Grant Reviews**

ACS-IRG, 2017 (2 reviews)  
Biostatistics and Bioinformatics Department, 2017 (2 reviews)  
Skin SPORE, 2017 (2 reviews)  
FORMA Grant Review, 2016  
BMS Rare Population Malignancies Program (RPMP), 2015-2016  
Skin Spore Grant Reviews, 2014-2016  
NFGC Grant Reviews, 2010  
ACS-IRG Grant Reviewer, Moffitt Cancer Center, 2006-2007  
DIO RAF2 Grant Reviews, Moffitt Cancer Center, 2007

### **University of North Carolina Service**

#### Department

2004 – 2005 Chair, Research Faculty Search Committee  
2002 – 2005 Member, Graduate Studies Committee, UNC  
1999 – 2000 Chair, Research Faculty Search Committee, UNC  
1998 – 1999 Chair, Research Faculty Search Committee, UNC  
1995 – 1997 Chair, Biostatistics Seminar Committee, UNC

#### University

2002 – 2005 Member, Data and Safety Monitoring Committee  
1997 – 2005 Member, Line Berger Comprehensive Cancer Center Program Planning Committee  
1995 – 2005 Member, Protocol Review Committee, Lineberger Comprehensive Cancer Center  
1995 – 2005 Director of the Biostatistics Shared Resource, Lineberger Comprehensive Cancer Center, 1995-2005

### **Profession:**

#### **State**

2000 President of the North Carolina Chapter of the American Statistical Association  
1987 – 1990 President of the Western Tennessee Chapter of the American Statistical Association  
1986 – 1987 Secretary of the Western Tennessee Chapter of the American Statistical Association  
1985 – 1986 Secretary/Treasurer of the Western Tennessee Chapter of the American Statistical Association

#### **National**

2017 Second Annual Statistical Practice in Cancer Conference, March 3, 2017  
Moffitt Cancer Center (Conference Organizer)  
2016 First Annual Statistical Practice in Cancer Conference, May 13, 2016  
Moffitt Cancer Center (Conference Organizer)  
2011 Conference on Statistical Practice Organizing Committee

- 2007 – 2008 Program Chair for 2008 Joint Statistical Meetings, Statistician Sports Section, American Statistical Association
- 2008 Organizer of one of two “Late Breaking Sessions” for the Joint Statistical Meetings (upon the invitation for overall JSM organizer, Dr. Russell Lenth) on Steroids and Baseball
- 2005 – 2006 Present Statistical Editor, Cancer Control
- 2005 – 2007 Vice Chair, Council of Chapters Governing Board, District 5 (Southeast, US.) American Statistical Association
- 2003 President, Statistics in Sports Section of the American Statistical Association
- 1999 – 2001 Statistics Section Council, American Public Health Association (1999-2001)

**Manuscript Reviewer**

**Medical** – Journal of Clinical Oncology, Medical and Pediatric Oncology, European Journal of Cancer, Health Education Research, Lung Cancer, Public Health Nutrition, Cancer Prevention and Detection, Archives of Environmental Contamination and Toxicology, BMC Medical Informatics and Decision Making, Therapeutic Innovation and Regulatory Science

**Statistical** – Journal of the American Statistical Association, Biometrics, Statistics in Medicine, Computational Statistics and Data Analysis, American Statistician, Drug Information Journal, Statistical Modeling, Cancer Control Journal, Clinical Trials and Scientometrics

2018	JNCI	March
	Gut	March
	Int J of Tech Assessment	March
	JNCI	July
	BMC Medical Genetics	August
	BMC Med Inf & Dec Making	August
2017	Oncotarget	January
	Clinical Trials	June
	PLoS1	September
	Future Oncology	October
	JNCI	October
	Int J Tech Assessment	November
	Scientific Reports	November
	Gastrointestinal Res & Pract	November
2016	Oncogene	May, June
	JNCI	October
	Oncotarget	November
	Cancer Biomarkers	December
2015	PLoS One	January
	Nucleic Acids Research	August, December
	JAMA-Oncology	June
2014	Statistics in Medicine	February
	PLoS One	August, September
	Scientometrics	September

	JAMA	December
2013	Statistics in Medicine	April, June, November
	Clinical Trials	June
	Therapeutic Innovations	April

**Book** – Johns Hopkins University Press, Oxford University Press, Princeton University Press

### **Grant Reviewer**

Biostatistical Methods and Research Design (BMRD) Section, March, 2017  
NCI (CISNET) Cancer Interventional Surveillance Monitoring Network, April, 2015  
CDMRP-CRMRP-RTRA-PCS-2 grant review (12 grant reviews)  
Israel Science Foundation, online review, February, 2014  
Member, Cancer Biomarkers Study Section, July, 2010 – February 2014 (3 review meetings/year)  
Cancer Biomarkers Study Section (ad hoc member), October, 2009  
Susan Koman Grants, September, 2009  
NCI Challenge Grants, June, 2009  
Susan Koman Breast Cancer Grants, November, 2008  
NCI Nanotechnology Grant, July 2005  
NCI/Avon Breast Cancer Grant, January, 2003; January, 2005  
NCI PO1 Grants, October, 2002; January, 2003; August, 2003; October, 2003; December, 2003  
NCI Cancer Center Core Grant, October, 2002  
NCI CONC Review Group, July, 2002  
NCI (CISNET) Cancer Interventional Surveillance Monitoring Network, Second Round, March, 2002  
NCI (CISNET) Cancer Interventional Surveillance Monitoring Network, First Round, March, 2000

### **Review Boards**

2005                      Member, Data and Safety Monitoring Board, for the NCI-funded clinical trial: An International multicenter phase III study of chemoradiotherapy plus hyperthermia for locally advanced cervical cancer. PI: Mark Dewhirst, M.D., Duke University.

2004 – 2005            Member, External Advisory Committee for the Carolina Center for Aids Research (CFAR).

### **Data Safety Monitoring Board**

2015-present      Testosterone Plus Finasteride Treatment after Spinal Cord Injury, North Florida/South Georgia Veterans Health System, Study # B1449-01, Dr. Joshua Yarrow (PI)

**Professional Association Memberships**

1999 – present	Member, Delta Omega Theta Chapter
1984 – present	Member, American Statistical Association
1981 – present	Member, Biometric Society
1993 – 2001	Member, Sigma Xi
1999 – 2001	Member, American Public Health Association
1979 – 1981	Member, Pi Mu Epsilon

**External Review for Promotion and/or Tenure**

2016	University of California-Irvine Georgetown University Fox Chase Cancer Center
2015	University of Kentucky University of New Mexico Vanderbilt University Boston University
2014	Georgetown University University of South Florida Emory University
2013	University of Hawaii Cancer Center Harvard University University of Miami Oregon Health & Science University Georgetown University
2011	University of South Florida
2010	Georgetown University Medical University of South Carolina
2009	Moffitt Cancer Center
2008	University of Hawaii at Manoa Syracuse University
2007	Wayne State University

**Peer-Reviewed Research Articles**

1. **Schell MJ** and Singh B. Robustness of  $X^2$  and  $E^2$ : A case for a ranked test in order-restricted inference. *Advances in order restricted inference*. Eds. R. Dykstra, T Robertson and F.T. Wright. *Springer-Verlag 1986*; pp. 184-202
2. Meyer WH, **Schell MJ**, Kumar APM, Rao BN, Green AA, Champion J, Pratt CB. Thoracotomy for pulmonary metastatic osteosarcoma. *Cancer 1987*; 59:374-379
3. Hughes WT, Rivera GK, **Schell MJ**, Thornton D, Lott L. Successful intermittent-chemoprophylaxis for pneumocystis carinii pneumonitis. *N Engl J Med 1987 Jun*; 316:1627-1632. PMID: 3495732

4. Ribiero RC, Pui C-H and **Schell MJ**. Vertebral collapse as a presenting feature of acute lymphoblastic leukemia in children. *Cancer* 1988 Feb; 61:589-592. PMID: 3276382
5. Pui C-H, Kalwinsky DK, **Schell MJ**, Mason CA, Dahl GV. Acute nonlymphoblastic leukemia in infants: Clinical presentation and outcome. *J Clin Oncol* 1988; 6:1008-1013
6. Kalwinsky D, Mirro J, **Schell MJ**, Behm F, Mason C, Dahl GV. Early intensification of chemotherapy for childhood acute nonlymphoblastic leukemia: Improved remission induction with a five-year regimen including etoposide. *J Clin Oncol* 1988; 6:1134-1143
7. **Schell MJ** and Morrison M. A statistical model for the timing mechanism of the erythrocyte life span (with commentary). *Blood Cells* 1988; 14:297-311. PMID: 3179458
8. Lauer ME, Mulhern RK, **Schell MJ**, Camitta BM. Long-term follow up of parental adjustment following a child's death at home or hospital. *Cancer* 1989; 63:988-994
9. Carter M, Kalwinsky DK, Dahl GV, Santana V, Mason CA, **Schell MJ**. Childhood acute promyelocytic leukemia: a rare variant of nonlymphoid leukemia with distinctive clinical and biologic features. *Leukemia* 1989 Apr; 3:298-302. PMID: 2927178
10. Hutchison RE, Kunkel KD, **Schell MJ**, Jackson CW, Nelson EJ, Wang WC, Fischl SJ, Taylor LB, Garcez RB, Pui C-H. Beneficial effect of brief pre-transfusion incubation of platelets at 37 degrees C. *Lancet* 1989 May; i:986-988. PMID: 2565517
11. **Schell MJ**, McHaney VA, Green AA, Kun LE, Hayes FA, Horowitz M, Meyer WH. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. *J Clin Oncol* 1989; 7:754-760
12. Pinto A, Grant LH, Hayes FA, **Schell MJ**, Parham DM. Immunohistochemical expression of neuron-specific enolase and Leu 7 in Ewing's sarcoma of bone. *Cancer* 1989 Sep; 64:1266-1273. PMID: 2670185
13. **Schell MJ** and Leysieffer FW. An increasing failure rate approach to low dose extrapolation. *Biometrics* 1989; 45:1117-1124.
14. Ribeiro RC, Sandrini R, **Schell MJ**, Lacerda L, Sambaio GA, Cat I. Adrenocortical carcinoma in children: study of 40 cases. *J Clin Oncol* 1990 Jan; 8:67-74. PMID: 2295912
15. Kalwinsky DK, Raimondi SC, **Schell MJ**, Mirro J, Santana VM, Behm F, Dahl GV, Williams D. Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia. *J Clin Oncol* 1990 Jan; 8:75-83. PMID: 2295913
16. Pui C-H, Behm FG, Singh B, **Schell MJ**, Williams DL, Rivera GK, Kalwinsky DK, Sandlund JT, Crist WM, Raimondi SC. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. *Blood* 1990 Jan; 75:174-179. PMID: 2136802
17. Pui C-H, Behm FG, Singh B, Rivera GK, **Schell MJ**, Roberts WM, Crist WM, Mirro J. Myeloid-associated antigen expression lacks prognostic value in childhood acute

- lymphoblastic leukemia treated with intensive multiagent chemotherapy. *Blood* 1990 Jan; 75:198-202. PMID: 2294988
18. Dahl GV, Kalwinsky DK, Mirro J, Look AT, Mason C, **Schell MJ**, Johnson FL, Thomas ED. A comparison of intensive post-remission chemotherapy or allogeneic bone marrow transplantation to prevent initial leukemia relapse in childhood acute nonlymphocytic leukemia. *J Clin Oncol* 1990; 8:295-303
  19. Koehler M, **Schell MJ**, Behm FG, Raimondi SC, Woodruff LS, Mirro J. Expression of a novel surface antigen MKW in childhood acute leukemia has prognostic significance. *Leukemia* 1991 Jan; 5:41-48. PMID: 1999957
  20. Wang W, Kovnar E, Tonkin I, Mulhern R, Langston J, Day S, **Schell M**, Williams J. High risk of recurrent stroke after stopping transfusion therapy in sickle cell patients transfused for 5-12 years. *J Peds* 1991; i:377-382
  21. Schriock EA, **Schell MJ**, Carter M, Hustu O, Ochs JJ. Abnormal growth patterns and adult short stature in long-term survivors of childhood leukemia. *J Clin Oncol* 1991 Mar; 9:400-405. PMID: 1999710
  22. Santana VM, Mirro J, Harwood FC, Cherrie J, **Schell M**, Kalwinsky D, Blakley RL. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. *J Clin Oncol* 1991 Mar; 9:416-422. PMID: 1671875
  23. Mahmoud H, **Schell M**, Pui C-H. Cholelithiasis after cancer treatment. *Cancer* 1991; 67:1439-1442
  24. Pui C-H, **Schell MJ**, Vodian MA, Kline S, Mirro J, Crist WM, Behm FG. Serum CD4, CD8 and interleukin-2 receptor levels in childhood acute myeloid leukemia. *Leukemia* 1991 Mar; 5:249-254. PMID: 1901614
  25. Pui C-H, Raimondi SC, Head DR, **Schell MJ**, Rivera GK, Mirro J, Crist WM, Behm FG. Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. *Blood* 1991 Sep; 78:1327-1337. PMID: 1878594
  26. Relling MV, Cherrie J, **Schell MJ**, Petros WP, Meyer WM, Evan WE. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype American black versus white subjects. *Clin Pharmacol Ther* 1991 Sep; 50:308-313. PMID: 1680593
  27. Rao BN, Santana VM, Parham D, Pratt CB, Fleming ID, Hudson M, Fontanesi J, Philippe P, **Schell MJ**. Pediatric non-rhabdomyosarcomas of the extremities. *Arch Surg* 1991; 126:1490-1495
  28. **Schell MJ**, Ochs JJ, Schriock EA, Carter M. A method of predicting adult height and obesity in long-term survivors of childhood acute lymphoblastic leukemia. *J Clin Oncol* 1992 Jan; 10:128-133. PMID: 1727914
  29. Bean WJ, **Schell M**, Katz J, Kawaoka Y, Naeve C, Gorman O, Webster RG. Evolution of the H3 influenza virus hemagglutinin from human and nonhuman hosts. *J of Virol* 1992 Feb; 66:1129-1138. PMCID: PMC240817

30. Eguiguren JM, **Schell MJ**, Crist WM, Kunkel K, Rivera GK. Complications and outcome in childhood acute lymphoblastic leukemia with hyperleukocytosis. *Blood* 1992 Feb; 79:871-875. PMID: 1737097
31. Behm FG, Raimondi SC, **Schell MJ**, Look AT, Rivera GK, Pui C-H. Lack of CD45 antigen on blast cells in childhood acute lymphoblastic leukemia is associated with chromosomal hyperdiploidy and other favorable prognostic features. *Blood* 1992 Feb; 79:1011-1016. PMID: 1531305
32. Hurwitz CA, **Schell MJ**, Pui C-H, Crist WM, Behm F, Mirro J. Adverse prognostic features in 251 children treated for acute myeloid leukemia. *Med Pediatr Oncol* 1993; 21:1-7. PMID: 8426571
33. Singh B and **Schell MJ**. On power functions of the likelihood ratio tests for the simple loop order in normal means: Unequal sample sizes. *Stat Probabil Letters* 1992; 14:253-267
34. Pui C-H, Carroll AJ, Raimondi SC, **Schell MJ**, Head DR, Shuster JJ, Land VJ, Borowitz MJ, Link MP, Behm FG, Steuber P, Crist WM. Isochromosomes in childhood acute lymphoblastic leukemia: A collaborative study of 83 cases. *Blood* 1992 May; 79:2384-2391. PMID: 1571550
35. Stute N, Santana VM, Rodman JH, **Schell MJ**, Ihle J, Evans WE. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor (G-CSF) in children. *Blood* 1992 Jun; 79:2849-54. PMID: 1375115
36. Angel CA, Pratt CB, Rao BN, **Schell MJ**, Parham DM, Lobe TE, Fleming ID. Carcinoembryonic antigen (CEA) and carbohydrate (CA) 19-9 antigen as markers for colorectal carcinoma in children and adolescents. *Cancer* 1992 Mar; 69:1487-91. PMID: 1311626
37. Hurwitz CA, Krance R, **Schell MJ**, Santana VM, Brenner MK, Ribeiro R, Roberts WM, Mahmoud H, Belt J, Crom W, Shearer PD, Mirro J. Current strategies for treatment of acute myeloid leukemia at St. Jude Children's Research Hospital. *Leukemia* 1992; 6 Suppl 2:39-43. PMID: 1374492
38. Santana VM, Mirro J, Kearns C, **Schell MJ**, Crom W, Blakley RL. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. *J Clin Oncol* 1992 Mar; 10:364-370. PMID: 1346800
39. Santana VM, **Schell MJ**, Williams R, Bowman LC, Thompson EI, Brenner MK, Mirro J, Jr. Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors. *Bone Marrow Transpl* 1992 Nov; 10:457-462. PMID: 1464010
40. Singh B, **Schell MJ**, Wright FT. The power functions of the likelihood ratio tests for a simple tree ordering in normal means: Unequal weights. *Commun Stat Theory* 1993; A 22:425-449



41. Wile AG, Hourani L, **Schell MJ**. The contributions of patient factors, physician delay, and tumor biology to the outcome of gastric cancer. *Am Surgeon* 1993 Dec; 59:850-854. PMID: 8256942
42. Peabody TD, Monson D, Montag A, **Schell MJ**, Finn H, Simon MA. A comparison of the prognosis for deep and subcutaneous sarcomas of the extremities. *J Bone Joint Surg Am* 1994 Aug; 76(A):1167-1173. PMID: 8056797
43. Kimel S, Svaasand LO, Hammer-Wilson M, **Schell MJ**, Milner TE, Nelson JS, Berns MW. Differential vascular response to laser photothermolysis. *J Invest Dermatol* 1994 Nov; 103(5):693-700. PMID: 7963659
44. Kimel S, Svaasand LO, Milner TE, Hammer-Wilson M, **Schell MJ**, Nelson JS, Berns MW. Laser photothermolysis of single blood vessels in the chick chorioallantoic membrane (CAM). *Proceedings of Laser Interaction with Hard and Soft Tissue* 1994; pp. 216-227
45. Wyss P, Tromberg BJ, Wyss MT, Krasieva T, Liaw L, **Schell M**, Berns MW, Tadir Y. Photodynamic destruction of endometrial tissue using topical 5-aminolevulinic acid (5-ala) in rats and rabbits. *Am J Obstet Gynecol* 1994 Nov; 171:1176-1183. PMID: 7977515
46. Monk BJ, Chapman JA, Johnson GA, Brightman BK, Wilczynski SP, **Schell MJ**, DiSaia PJ, Berman ML, Manetta A, Fan H. Correlation of c-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer. *Am J of Obstet Gynecol* 1994 Nov; 171(5):1193-1198. PMID: 7977518
47. Van Nostrand KM, Lucci JA 3rd, **Schell M**, Berman ML, Manetta A, DiSaia PJ. Primary vaginal melanoma: improved survival with radical pelvic surgery. *Gynecol Oncol* 1994 Nov; 55(2):234-237. PMID: 7959290
48. Dantas ZN, Araujo E, Berns MW, Tadir Y, **Schell MJ**, Stone SC. Effect of freezing on the relative escape force of sperm as measured by a laser optical trap. *Fertil Steril* 1995 Jan; 63:185-188. PMID: 7805910
49. Wong DH, Weber EC, **Schell MJ**, Wong AB, Anderson CT, Barker SJ. Factors associated with post-operative pulmonary complications in patients with severe COPD. *Anesth Analg* 1995 Feb; 80:276-284. PMID: 7818113
50. Singh B, **Schell MJ** and Wright FT. Approximations to the powers of the likelihood ratio tests: The loop ordering and slippage alternatives. *Commun Simul* 1995; 24(1):91-109
51. Stute N, Furman WL, **Schell MJ**, Evans WE. Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in children after intravenous and subcutaneous administration. *J Pharmac Sci* 1995 Jul; 84(7):824-828. PMID: 7562431
52. Wilder-Smith P, Arrastion AM, **Schell MJ**, Liaw LM, Grill G, Berns MW. Effect of ND: YAG laser irradiation and root planing on the root surface and thermal effects. *J Periodontol* 1995 Dec; 66(12):1032-1039. PMID: 8683415

53. Manetta A, Schubbert T, Chapman J, **Schell MJ**, Peng YM, Liao SY, Meyskens FJ. Beta-carotene treatment of cervical intraepithelial neoplasia: A phase II study. *Cancer Epidemiol Biomarkers* 1996 Nov; 5:929-932. PMID: 8922303
54. **Schell MJ** and Singh B. The reduced monotonic regression method. *J Am Statist Assoc.* 1997; 92:128-135
55. Atiba JO, Manzardo AM, Thiruvengadam R, **Schell MJ**, Meyskens Jr FL. Restoration of oral all-*trans* retinoic acid bioavailability after a brief drug holiday. *Am J Therapeut* 1997 Apr; 4:134-140. PMID: 10423603
56. George S, **Schell MJ**, Detterbeck FC, Socinski MA. Adjuvant chemotherapy for resected non-small cell carcinoma of the lung: why we still don't know. *Oncologist* 1998; 3:35-44. PMID: 10388082
57. Kinney AY, Vernon SW, Shui W, Weber DV, **Schell M**, Vogel VG. Validation of a model predicting enrollment in a chemoprevention trial for breast cancer. *Cancer Epidemiology, Biomarkers & Prevention* 1998 Jul; 7(7):591-595. PMID: 9681527
58. Pisano ED, Earp J, **Schell M**, Vokaty K, Denham A. Screening behavior of women after a false-positive mammogram. *Radiology* 1998 Jul; 208(1):245-249. PMID: 9646820
59. Wester RC, Xiaoying H, Maibach HI, Bell K, **Schell MJ**, Northington DJ, Strong PL, Culver BD. In vivo percutaneous absorption of boron as boric acid, borax and disodium octaborate tetrahydrate in humans: a summary. *Biol Trace Elem Res* 1998; 66:101-110. PMID: 10050912
60. Wester RC, Hartway T, Maibach HI, **Schell MJ**, Northington DJ, Culver BD, Strong PL. In vitro percutaneous absorption of boron as boric acid, borax and disodium octaborate tetrahydrate in human skin: a summary. *Biol Trace Elem Res* 1998 winter; 66:111-120, 1998. PMID: 10050913
61. Godley PA and **Schell MJ**. Adjusted odds ratios under nondifferential misclassification: application to prostate cancer. *J Clin Epid* 1999 Feb; 52(2):129-136. PMID: 10201653
62. Wester, RC, Hui X, Hartway T, Maibach H, Bell K, **Schell MJ**, Northington DJ, Strong P, Culver BD. In vivo percutaneous absorption of boric acid, borax, and disodium octaborate tetrahydrate in humans compared to *in vitro* absorption in human skin from infinite and finite doses. *Toxicol Sci* 1998 Sep; 45: 42-51. PMID: 9849109
63. Bic Z, Blix GG, Hopp HP, Leslie FM, **Schell MJ**. The influence of a low-fat diet on incidence and severity of migraine headaches. *J Women Health Gen-B* 1999 Jun; 8(5):623-630. PMID: 10839648
64. Braeuning MP, Cooper HW, O'Brien S, Burns CB, Washburn DB, **Schell MJ**, Pisano ED. Effects of processing conditions on mammographic image quality. *Acad Radiol* 1999 Aug; 6(8): 464-470. PMID: 10480042

65. Huang WY, Newman B, Millikan RC, Conway K, Hulka BS, **Schell MJ**, Liu ET. Risk of breast cancer according to the status of HER-2/neu oncogene amplification. *Cancer Epid Biomark* 2000 Jan; 9:(1) 65-71. PMID: 10667465
66. Pisano ED, **Schell M**, Rollins J, Burns CB, Hall B, Lin Y, Braeuning MP, Burke E, Holliday J. Has the mammography quality standards act affected the mammography quality in North Carolina?. *Am J Roentgenol* 2000 Apr; 174:(4)1089-1091. PMID: 10749257
67. Huang WY, Newman B, Millikan RC, **Schell MJ**, Hulka BS, Moorman PG. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. *Am J Epidemiol* 2000 Apr; 151:(7) 703-714. PMID: 10752798
68. Stark A, Hulka BS, Joens S, Novotny D, Thor AD, Wold, LE, **Schell MJ**, Melton LJ, Liu ET, Conway K. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. *J Clin Oncol* 2000 Jan; 18 (2): 267-274. PMID: 10637239
69. Brylawski BP, Cohen SM, Cordeiro-Stone M, **Schell MJ**, Kaufman DG. On the relationship of matrix association and DNA replication. *Crit Rev in Eukar Gene E* 2000; 10(1):91-99. PMID: 10813397
70. Osann KE, Lowery JT, **Schell MJ**. Small cell lung cancer in women: risk associated with smoking, prior respiratory disease, and occupation. *Lung Cancer* 2000 Apr; 28 (1):1-10. PMID: 10704703
71. Braeuning MP, O'Malley M, **Schell MJ**, O'Brien S, Pisano ED, Earp J. Informing patients of diagnostic mammography results: mammographers opinions. *Acad Radiol* 2000 May; 7: 335-340. PMID: 10803613
72. Socinski MA, Rosenman JG, Halle J, Russo S, Rivera MP, Clark J, Limentani S, Frazier R, Mitchell W, **Schell MJ**, Detterbeck FC. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage III A/B non-small cell lung cancer: A modified phase I trial. *Cancer* 2000 Aug; 89(3):534-542. PMID: 10931452
73. Duell EJ, Millikan RC, Savitz DA, Newman, Smith JC, **Schell MJ**, Sandler DP. A population-based, case-control study of farming and breast cancer in North Carolina. *Epidemiology* 2000 Sep; 11:523-531. PMID: 10955404
74. Gillenwater HH, Tynan M, Natoli S, **Schell MJ**, Socinski MA. Second-Line gemcitabine in refractory stage IV non-small-cell lung cancer: A Phase II Trial. *Clin Lung Cancer* 2000 Nov; 2 (2):133-138. PMID: 14731324
75. Serody JS, Berrey MM, Albritton K, O'Brien SM, Capel EP, Bigelow SH, Weber DJ, Gabriel DA, Wiley, JM, **Schell MJ**, Gilligan PH, Shea TC. Utility of obtaining blood cultures in febrile neutropenic patients undergoing bone marrow transplantation. *Bone Marrow Transpl* 2000 Sep; 26(5):533-538. PMID: 11019843
76. Serody JS, Sparks, SD, Lin YH, Capel EJ, Bigelow SH, Kirby SL, Gabriel DA, Wiley JM, Brecher ME, **Schell MJ**, Folds J, Shea TC. Comparison of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells and G-CSF-stimulated bone

- marrow as a source of stem cells in HLA-matched sibling transplantation. *Biol Blood Mar Transplant* 2000; 6(4A):434-440. PMID: 10975512
77. O'Malley MS, Earp JA, Tropman S, **Schell MJ**, Mathews HF, Mitchell J. The association of race/ethnicity, socioeconomic status, and physician recommendation for mammography: who gets the message about breast cancer screening? *Am J Public Health* 2001 Jan; 91(1):49-54. PMID: PMC1446507
  78. Duell EJ, Millikan RC, Savitz DA, **Schell MJ**, Newman B, Tse CKJ, Sandler DP. Reproducibility of reported farming activities and pesticide use among breast cancer cases and controls: A comparison of two modes of data collection. *Ann Epidemiol* 2001 Apr; 11(3): 178-185. PMID: 11248581
  79. Godley PA, Rathore SS, Kshirsagar AV, **Schell MJ**, Amamoo MA, Freeman J, Harris RP. Retrospective classification of prostate-specific antigen test: Differentiating screening from diagnostic clinical encounters. *J Clin Epidemiol* 2001 Sep; 54 (9):884-888. PMID: 11520647
  80. Pisano ED, Britt GG, Lin Y, **Schell MJ**, Burns CB, Brown ME. Factors affecting Phantom scores at annual mammography facility inspections by the US Food and Drug Administration. *Acad Radiol* 2001 Sep; 8(9):864-870. PMID: 11724041
  81. Yankaskas BC, **Schell MJ**, Bird RE, Desrouchers DA. Reassessment of missed breast cancers from the routine practice of screening mammography: A community-based study. *Am J of Roentgenol* 2001 Sep; 177(3):535-541. PMID: 11517043
  82. Yankaskas BC, Cleveland RJ, **Schell MJ**, Kozar R. Association of recall rates with sensitivity and positive predictive values of screening mammography. *AJR Am J Roentgenol* 2001 Sep; 177(3): 543-549. PMID: 11517044
  83. Charles MJ, **Schell MJ**, Willman E, Gross HB, Lin Y, Sonnenberg S, Graham ML. Organochlorines and 8-Hydroxy-2' deoxyguanosine (8-OhdG) in cancerous and noncancerous breast tissue: Do the data support the hypothesis that oxidative DNA damage caused by organochlorines affects breast cancer? *Arch Environ Con Tox* 2001 Oct; 41(3):386-395. PMID: 11503078
  84. Socinski MA, Rosenman JG, Halle J, **Schell MJ**, Lin Y, Russo S, Rivera MP, Clark J, Limentani S, Fraser R, Mitchell W, Detterbeck FC. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable Stage IIIA/B nonsmall cell lung carcinoma – A modified Phase I/II trial. *Cancer* 2001 Sep; 92(5):1213-1223. PMID: 11571735
  85. Keefe KA, **Schell MJ**, Brewer C, McHale M, Brewster W, Chapman JA, Rose GS, McMeeken DS, Lagerberg W, Peng YM, Wilczynski SP, Anton-Culver H, Meyskens FL, Berman ML. A randomized, double blind, phase III trial using oral-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. *Cancer Epidem Biomar* 2001 Oct; 10(10):1029-1035. PMID: 11588128
  86. Poole, ME, Sailer SL, Rosenman JG, Tepper JE, Weissler MC, Shockley WW, Yarbrough WG, Pillsbury HC, **Schell MJ**, Bernard SA. Chemoradiation for locally advanced squamous

- cell carcinoma of the head and neck for preservation and palliation. *Archives of Otolaryngology-Head & Neck Surgery* 2001 Dec; 127(12):1446-50. PMID: 11735812
87. Bloedon LT, Jeffcoat AR, Lopaczynski W, **Schell MJ**, Black TM, Dix KJ, Thomas BF, Albright C, Busby MG, Crowell JA, Zeisel SH. Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women. *Am J Clin Nutr* 2002 Nov; 76(5):1126-1137. PMID: 12399289
  88. Socinski MA, **Schell MJ**, Peterman A, Bakri K, Yates S, Gitten R, Unger P, Lee J, Lee JH, Tynan M, Moore M, Kies MS. Phase III trial comparing a defined duration of Therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV Non-Small-Cell Lung Cancer. *J Clin Oncol* 2002 Mar; 20(5):1335-1343. PMID: 11870177
  89. Socinski MA, **Schell MJ**, Bakri K, Peterman A, Lee JH, Unger P, Yates S, Hudgens S, Kies MS. Second-line, low-dose, weekly paclitaxel in patients with Stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. *Cancer* 2002 Sep; 95:1265-1273. PMID: 12216094
  90. McHale MT, Berman ML, Keefe KA, **Schell MJ**, Peng YM, Monk BJ. Influence of serum and tissue micronutrient levels on the regression of untreated cervical intraepithelial neoplasia 2 and 3. *J Low Genit Tract Dis* 2002 Oct; 6(4):220-224. PMID: 17051026
  91. Socinski MA, Neubauer MA, Olivares J, Ketchel S, Tynan M, Moore M, Lee JH, Davis K, **Schell M**, Garfield D. Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer. *Lung Cancer* 2003 Apr; 40(1):91-97. PMID: 12660013
  92. Abrahamson PE, Dunlap LA, Amamoo MA, **Schell MJ**, Braeuning MP, Pisano ED. Factors predicting successful needle-localized breast biopsy. *Acad Radiol* 2003 Jun;10(6):601-606. PMID: 12809412
  93. Hensing TA, Peterman AH, **Schell MJ**, Lee JH, Socinski, MA. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. *Cancer* 2003 Aug; 98(4): 779-88. PMID: 12910523
  94. Mohler JL, Gaston KE, Moore DT, **Schell MJ**, Cohen BL, Weaver C, Petrusz P. Racial differences in prostate androgen levels in men with clinically localized prostate cancer. *Journal of Urology* 2004 Jun; 171(6):2277-2280. PMID: 15126802
  95. Hensing TA, **Schell MJ**, Lee JH, Socinski, MA. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. *Lung Cancer* 2005 Feb; 47(2):253-259. PMID: 15639724
  96. Ivanova A, Qaqish BF, **Schell MJ**. Continuous toxicity monitoring in phase II trials in oncology. *Biometrics* 2005 Jun; 61(2):540-545. PMID: 16011702
  97. Kondo S, Wakisaka N, **Schell MJ**, Horikawa T, Sheen TS, Sato H, Furukawa M, Pagano JS, Yoshizaki T. Epstein-Barr virus latent membrane protein 1 induces the matrix metalloproteinase-1 promoter via an Ets binding site formed by a single nucleotide

- polymorphism: enhanced susceptibility to nasopharyngeal carcinoma. *Int J Cancer* 2005 Jun; 115(3):368-76. PMID: 15688379
98. Titus MA, **Schell MJ**, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. *Clinical Cancer Research* 2005 Jul; 1;11(13):4653-4657. PMID: 16000557
  99. Titus MA, Gregory CW, Ford OH, **Schell MJ**, Maygarden SJ, Mohler JL. Steroid 5 $\alpha$ -reductase isozymes I and II in recurrent prostate cancer. *Clinical Cancer Research* 2005 Jun; 11(12):4365-4371. PMID: 15958619
  100. Graham DK, Salzberg DB, Kurtzberg J, Sather S, Matsushima GK, Keating AK, Liang, X, Lovell MA, Williams SA, Dawson TL, **Schell MJ**, Anwar AA, Snodgrass HR, Earp HS. Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. *Clinical Cancer Research* 2006 May; 12(9):2662-2669. PMID: 16675557
  101. Stinchcombe TE, Choi J, **Schell MJ**, Mears A, Jones PE, Nachtsheim RV, Socinski MA. Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status. *Lung Cancer* 2006 Feb; 51(2):237-243. PMID: 16378657
  102. Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, **Schell MJ**, Dalton WS, Sullivan DM. ABCG2 expression, function, and promoter methylation in human multiple myeloma. *Blood* 2006 Dec; 108(12):3381-3389. PMCID: PMC1895461
  103. Pavic D, **Schell MJ**, Dancel RD, Sultana S, Lin L, Sejpal SV, Pisano ED. Comparison of three methods to increase knowledge about breast cancer and breast cancer screening in screening mammography patients. *Acad Radiol* 2007 May; 14(5):533-536. PMID: 17434069
  104. **Schell MJ**, Yankaskas BC, Ballard-Barbash R, Qaqish BF, Barlow WE, Rosenberg RD, Smith-Bindman R. Evidence-based target recall rates for screening mammography. *Radiology* 2007 Jun; 243(3):681-689. PMID: 17517927
  105. Singh B, Halabi S, **Schell M**. Sample size in clinical trials when population means are subject to a particular order: One sided order alternatives. *Journal of Applied Statistics* 2008; 35(4)
  106. Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, **Schell MJ**, Antonia SJ, Bepler G. Phase II trial of docetaxel and gefitinib in the first-line treatment of patients with advanced non small-cell lung cancer (NSCLC) who are 70 years of age or older. *Cancer* 2008 May; 112(9):2021-2029. PMID: 18300255
  107. Tanvetyanon T, Robinson LA, **Schell MJ**, Strong VE, Kapoor R, Coit DG, Bepler G. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: A systematic review and pooled analysis. *Journal of Clinical Oncology* 2008 Mar; 26(7):1142-1147. PMID: 18309950
  108. Zheng Z, Li X, **Schell MJ**, Chen T, Boulware D, Robinson L, Sommers E, Bepler G. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. *Cancer* 2008 Jun; 112(12):2765-2773. PMCID: PMC3857609

109. Hozo I, **Schell MJ**, Djulbegovic B. Decision-making when data and inferences are not conclusive: Risk-benefit and acceptable regret approach. *Seminars in Hematology* 2008 Jul; 45(3):150-159. PMID: 18582621
110. Chen DT, **Schell MJ**, Chen JJ, Fulp WJ, Eschrich S, Yeatman T. A predictive risk probability approach for microarray data with survival as an endpoint. *J Biopharm Stat* 2008; 18(5):841-852. PMCID: PMC2717790
111. Ghosh M and **Schell MJ**. A conversation with Pranab Kumar Sen. *Statistical Science* 2008; 23(4):548-564
112. Reynolds C, Obasaju C, **Schell MJ**, Li X, Zheng Z, Boulware D, Caton JR, DeMarco LC, O'Rourke MA, Shaw Wright G, Boehm KA, Asmar L, Bromund J, Peng G, Monberg MJ, Bepler, G. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. *J Clin Oncol* 2009 Dec; 27(34):5808-5815. PMCID: PMC2793001
113. Barami K, Sloan AE, Rojiani A, **Schell MJ**, Staller A, Brem S. Relationship of gliomas to the ventricular walls. *J Clin Neurosci* 2009 Feb; 16(2):195-201. PMID: 19097905
114. Guo JP, Shu SK, He L, Lee YC, Kruk PA, Grenman S, Nicosia SV, Mor G, **Schell MJ**, Coppola D, Cheng JQ. Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. *Am J Pathology* 2009 Jul; 175(1):324-333. PMCID: PMC2708818
115. Gao J, Zheng Z, Rawal B, **Schell MJ**, Bepler G, Haura EB. Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells. *Cancer Biology & Therapy* 2009 Sep; 8(17):1-9. PMCID: PMC3839311
116. Lee JH, **Schell MJ**, Roetzheim R. Analysis of group randomized trials with multiple binary endpoints and small number of groups. *PLoS One* 2009 Oct; 4(10):e7265. PMCID: PMC2760209
117. Johnson HW, **Schell MJ**. Neuronal IP3 3-Kinase is an F-actin-bundling protein: role in dendritic targeting and regulation of spine morphology. *Mol Biol Cell* 2009 Dec; 20(24): 5166-80. PMCID: PMC2793293
118. Lee JH, Miladinovic B, **Schell MJ**. Statistical tutorial notes: Analysis of two group comparisons, a practical guide. *Medical Problems of Performing Artists*, 2009; 166-169
119. Metro G, Zheng Z, Fabri A, **Schell M**, Antoniani B, Mottolese M, Monteiro AN, Vici P, Lara Rivera S, Boulware D, Cognetti F, Bepler G. In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. *Cancer Invest* 2010 Feb; 28(2):172-180. PMCID: PMC3565222
120. Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, **Schell MJ**, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung

- cancer. *The Journal of Clinical Oncology* 2010 Mar; 28(8):1387-1394. PMID: PMC3040065
121. Chen JJ, Roberson PK, **Schell MJ**. The false discovery rate: A key concept in large-scale Genetic Studies. *Cancer Control* 2010 Jan; 17(1):58-62. PMID: 20010520
  122. Chiappori AA, Zheng Z, Chen T, Rawal B, **Schell MJ**, Mullaney BP, Bepler G. Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer. *Journal of Thoracic Oncology* 2010 Apr; 5(4):484-490. PMID: PMC2861290
  123. Gergis U, Markey K, Greene J, Kharfan-Dabaja M, Field T, Wetzstein G, **Schell MJ**, Huang Y, Anasetti C, Perkins J. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. *Bone Marrow Transplant* 2010 Apr; 45(4):662-667. PMID: PMC2850960
  124. **Schell MJ**. Identifying key statistical papers from 1985 to 2002 using citation data for applied biostatisticians. *The American Statistician* 2010; 64(4):310-317
  125. Bepler G, Olaussen KA, Vataire A-L, Soria J-C, Zheng Z, Dunant A, Pignon J-P, **Schell MJ**, Fouret P, Pirke R, Filipits M, Brambilla E. ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative *in situ* analysis. *Am Journal of Pathology* 2011 Jan; 178(1):69-78. PMID: PMC3069904
  126. Turaga KK, Malafa MP, Jacobsen PB, **Schell MJ**, Sarr MG. Suicide in patients with pancreatic cancer. *Cancer* 2011 Feb; 117(3):642-647. PMID: PMC4704452
  127. Barlogie B, Bolejack V, **Schell M**, Crowley J. Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. *Ann Hematol* 2011 Apr; 90(4):423-428. PMID: PMC3053415
  128. Djulbegovic B, Kumar A, Magazin A, Schroen AT, Soares H, Hozo I, Clarke M, Sargent D, **Schell MJ**. Optimism bias leads to inconclusive results-an empirical study. *J Clin Epidemiol* 2011 Jun; 64(6): 583-593. PMID: PMC3079810
  129. Pillai S, Rizwani W, Li XL, Rawal B, Nair S, **Schell MJ**, Bepler G, Haura E, Coppola D, Chellappan S. ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nAChR and EGFR signaling. *Mol Cell Biol* 2011 Jul; 31(14):3052-3067. PMID: PMC3133413
  130. Mahmood ST, Agresta S, Vigil CE, Zhao X, Han G, D'Amato G, Calitri CE, Dean M, Garrett C, **Schell MJ**, Antonia S, Chiappori A. Phase II study of sunitinib malate, a multi-targeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on 3 prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. *International Journal of Cancer* 2011 Oct; 129(8):1963-69. PMID: PMC3776586
  131. Kumar NB, Crocker, T, Smith T, Pow-Sang, J, Spiess PE, Egan K, Quinn G, **Schell MJ**, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Slaton J, Anderson JK. Challenges and potential solutions to



- meeting accrual goals in a phase II chemoprevention trial for prostate cancer. *Contemporary Clinical Trials* 2012 Mar; 33(2):279-85. PMID: PMC3268882
132. Simon GR, **Schell MJ**, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis. *Cancer* 2012 May; 118(9):2525-2531. PMID: PMC3270127
133. Strosberg JR, Yeatman T, Weber J, Coppola D, **Schell MJ**, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D. A phase II study of RO4929097 in metastatic colorectal cancer. *Eur J Cancer* 2012 May; 48(7):997-1003. PMID: PMC4522922
134. Knapp CF, Sayegh Z, **Schell MJ**, Rawal B, Ochoa T, Sondak VK, Messina JL. Expression of CXCR4, E-cadherin, Bcl-2, and survivin in Merkel cell carcinoma: an immunohistological study using a tissue microarray. *Am J Dermatopathol* 2012 Aug; 34(6):592-6. PMID: PMC4634647
135. Zhang W, Tingare A, Ng DC, Johnson HW, Schell MJ, Lord RL, Chawla S. IP3-dependent intracellular Ca<sup>2+</sup> release is required for cAMP-induced c-fos expression in hippocampal neurons. *Biochem Biophys Res Commun* 2012 Aug; 425(2):450-5. PMID: 22846568
136. Strosberg JR, Weber JM, Choi J, Campos TL, Valone TL, Han G, **Schell MJ**, Kvols LK. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. *Ann Oncol* 2012 Sep. 23(9): 2335-41. PMID: PMC4559904
137. Han G, **Schell MJ**, Kim J. Comparing two exponential distributions using the exact likelihood ratio test. *Statistics in Biopharmaceutical Research* 2012 Oct;4(4), 348-356. PMID: PMC3693095
138. Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, **Schell MJ**, Sondak VK, Weber JS, Mulé JJ. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? *Scientific Reports* 2012; 2(765). PMID: PMC3479449
139. Kumar, NB, Crocker T, Smith T, Connors S, Pow-Sang J, Spiess PE, Egan K, Quinn G, **Schell MJ**, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F & Anderson K. Prostate cancer chemoprevention targeting men with high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical small acinar proliferation (ASAP): model for trial design and outcome measures. *J Clinical Trials* 2012 Jan; 2(1):100105. PMID: PMC3924733
140. Pidala J, Kim J, **Schell M**, Lee SJ, Hillgruber R, Nye V, Ayala E, Alsina M, Betts B, Bookout R, Fernandez HF, Field T, Locke FL, Nishihori T, Ochoa JL, Perez L, Perkins J, Shapiro J, Tate C, Tomblyn M, Anasetti C. Race/ethnicity affects the probability of finding an HLA-A, B, C, and DRB1 allele matched unrelated donor and likelihood of subsequent transplant utilization. *Bone Marrow Transplant* 2013 Mar; 48(3):346-350. PMID: PMC4500122

141. Gray J, Altiock S, Alexandrow MG, Walsh FW, Chen J, **Schell MJ**, Tai DF, Bepler G. Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers. *Cancer* 2013 Mar; 119(5):1023-1032. PMID: PMC3578040
142. Bepler G, Williams C, **Schell MJ**, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. *J Clin Oncol* 2013 Jul; 31(19):2404-12. PMID: PMC3691357
143. Etzkorn JR, Parikh RP, Marzban SS, Law K, Davis AH, Rawal B, **Schell MJ**, Sondak VK, Messina JL, Rendina LE, Zagar JS, Lien MH. Identifying risk factors using a Skin Cancer Screening Program. *Cancer Control* 2013 Oct; 20(4):248-254. PMID: PMC4516026
144. Creelan BC, Antonia S, Noyes D, Hunter TB, Simon GR, Bepler G, Williams CC, Tanvetyanon T, Haura EB, **Schell MJ**, Chiappori A. Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. *J Immunother* 2013 Oct; 36(8):442-50. PMID: PMC3846277
145. Li J, Bennett K, Stukalov A, Fang B, Zhang G, Yoshida T, Okamoto I, Kim JY, Song L, Bai Y, Qian X, Rawal B, **Schell M**, Grebien F, Winter G, Rix U, Eschrich S, Colinge J, Koomen J, Superti-Furga G, Haura EB. Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. *Mol Syst Biol* 2013 Nov; 5;9:705. PMID: PMC4039310
146. Han G, **Schell MJ**, Kim J. Improved survival modeling in cancer research using a reduced piecewise exponential approach. *Stat Med* 2014 Jan; 15;33(1):59-73. PMID: PMC3913785
147. Gray JE, Haura E, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenck M, Kish JA, Kreaehling J, Lush R, Neuger A, Tetteh L, Akar A, Zhao X, **Schell MJ**, Bepler G, Altiock S. A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors. *Clin Cancer Res* 2014 Mar; 15;20(6):1644-55. PMID: PMC4051132
148. Kothari N, **Schell MJ**, Teer JK, Yeatman T, Shibata D, Kim R. Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing. *J Clin Pathol* 2014 Sep; 67(9):764-767. PMID: PMC4743643
149. Rao NG, Trotti A, Kim J, **Schell MJ**, Zhao X, Amdur RJ, Brizel DM, Chambers MS, Caudell JJ, Miyamoto C, Rosenthal DI. Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancer. *Oral Oncology* 2014 Aug; 50(8):765-9. PMID: PMC4593395
150. Reich RR, Lengacher CA, Kip KE, Shivers SC, **Schell MJ**, Shelton MM, Widen RH, Newton C, Barta MK, Paterson CL, Farias JR, Cox CE, Klein TW. Baseline immune biomarkers as predictors of MBSR(BC) treatment success in off-treatment breast cancer patients. *Biological Research for Nursing* 2014 Oct; 16(4):429-37. PMID: PMC4604564. IF: 1.341

151. Lengacher CA, Reich RR, Kip KE, Barta M, Ramesar S, Paterson CL, Moscoso MS, Carranza I, Budhrani PH, Kim SJ, Park HY, Jacobsen PB, **Schell MJ**, Jim HS, Post-White J, Farias JR, Park JY. Influence of mindfulness-based stress reduction (MBSR) on telomerase activity in women with breast cancer (BC). *Biological Research for Nursing* 2014 Oct; 16(4):438-447. PMID: PMC4559344. IF: 1.341
152. Kumar, N B, Quinn, GP, Alexandrow, M, Gray J, **Schell M**, Sutton S, Haura EB. Chemoprevention trial feasibility using botanicals in exceptionally high risk populations for lung cancer. *Journal of Clinical Trials* 2014 Sep; 4(4). pii: 180. PMID: PMC4474484.
153. Cives M, Kunz PL, Morse B, Coppola D, **Schell MJ**, Campos T, Nguyen PT, Nandoskar P, Khandelwal V, Strosberg JR. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. *Endocrine-Related Cancer* 2015 Feb; 22(1):1-9. PMID: PMC4643672.
154. Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, Eysmans C, Richards A, **Schell MJ**, Fisher KJ, Horak CE, Inzunza HD, Yu B, Martinez AJ, Younos I, Weber JS. Safety, correlative markers and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. *Clinical Cancer Research* 2015 Feb; 21(4):712-20. PMID: PMC4620684
155. Gilbert J, **Schell MJ**, Zhao X, Murphy B, Tanvetyanon T, Leon ME, Neil Hayes D, Haigentz M Jr, Saba N, Nieva J, Bishop J, Sidransky D, Ravi R, Bedi A, Chung CH. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. *Oral Onco* 2015 Apr; 51: (4) 376-382. PMID: PMC4459134. IF:3.029
156. Pillai S, Trevino JG, Rawal B, Singh S, Kovacs M, Li XL, **Schell M**, Haura E, Bepler G, Chellappan S.  $\beta$ -arrestin-1 mediates nicotine-induced metastasis through E2F1 target genes that modulate epithelial-mesenchymal transition. *Cancer Res* 2015 Mar; 75(6) 1009-1020. PMID: PMC4359962. IF: 9.284
157. Mahipal A, Denson AC, Djulbegovic B, Lush R, Kumar A, Juan TH, **Schell MJ**, Sullivan DM. Effect of age on clinical outcomes in phase 1 trial participants. *Cancer Control* 2015 Apr; 22(2):235-41. PMID: 26068771.
158. Kothari N, Kim R, Jorissen RN, Desai J, Tie J, Wong HL, Farragher I, Jones I, Day FL, Li S, Sakthinandeswaren A, Palmieri M, Lipton L, **Schell M**, Teer JK, Shibata D, Yeatman T, Sieber OM, Gibbs P, Tran B. Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. *Acta Oncol* 2015 Apr; 54: (4) 487-492. PMID: PMC4743650. IF: 3.710
159. Kim R, **Schell MJ**, Teer JK, Greenawalt DM, Yang M, Yeatman TJ. Co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era. *PloS one* 2015 May; 10(5):e0126670. PMID: PMC4431733
160. Smith FO, Yue B, Marzban SS, Walls BL, Carr M, Jackson RS, Puleo CA, Padhya T, Cruse CW, Gonzalez RJ, Sarnaik AA, **Schell MJ**, DeConti RC, Messina JL, Sondak VK,

- Zager JS. Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma. *Cancer* 2015 Sep; 15;121(18):3252-60. PMID: PMC4904725
161. Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, Helal M, McLarty J, Williams CR, Schreiber F, Parnes HL, Sebti S, Kazi A, Kang L, Quinn G, Smith T, Yue B, Diaz K, Chornokur G, Crocker T, **Schell MJ**. Randomized, placebo-controlled trial of green tea catechins for prostate cancer prevention. *Cancer Prev Res (Phila)* 2015 Oct; 8(10):879-87. PMID: PMC4596745
162. **Schell MJ**, Yang M, Missiaglia E, Delorenzi M, Sonesson C, Yue B, Nebozhyn MV, Loboda A, Bloom G, Yeatman TJ. A composite gene expression signature optimizes prediction of colorectal cancer metastasis and outcome. *Clin Cancer Res* 2016 Feb; 1;22(3):734-45. PMID: PMC4802496
163. Weber J, Gibney G, Kudchadkar RR, Yu B, Cheng P, Martinez AJ, Kroeger J, Richards A, McCormick L, Moberg V, Cronin H, Zhao X, **Schell M**, Chen YA. Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. *Cancer Immunol Res* 2016 Apr; 4(4) 345-353. PMID: PMC4818672
164. **Schell MJ**, Yang M, Teer JK, Lo FY, Madan A, Coppola D, Monteiro AN, Nebozhyn MV, Yue B, Loboda A, Bien-Willner GA, Greenawalt DM, Yeatman TJ. A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. *Nat Commun* 2016 Jun; 7:11743. PMID: PMC4912618
165. Kumar NB, Pow-Sang J, Spiess PE, Park J, Salup R, Williams CR, Parnes H, **Schell MJ**. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. *Oncotarget*. 2016 Oct; 7(43):70794-70802. PMID: PMC5340117
166. Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, Ross HJ, Hann CL, Abu Hejleh T, Nieva J, Zhao X, **Schell M**, Sullivan DM. A randomized phase II study of linsitinib (OSI-906) versus topotecan in patients with relapsed small-cell lung cancer. *Oncologist* 2016 Oct; 21(10):1163-1164. PMID: PMC5061534
167. Omolo B, Yang M, Lo FY, **Schell MJ**, Austin S, Howard K, Madan A, Yeatman TJ. Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer. *BMC Med Genomics* 2016 Oct; 19;9(1):65. PMID: PMC5069826
168. Scott JG, Berglund A, **Schell MJ**, Mihaylov I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, Strom TS, Mellon E, Venkat P, Johnstone P, Foekens J, Lee J, Moros E, Dalton WS, Eschrich SA, McLeod H, Harrison LB, Torres-Roca JF. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. *Lancet Oncology* 2017 Feb; 18(2):202-211. PMID: 27993569. IF:33.9.
169. Leone A, Diorio G, Sexton W, **Schell M**, Alexandrow M, Fahey JW, Kumar NB. Sulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach. *Oncotarget* 2017 May; 23:8(21):35412-35424. PMID: PMC5471065. IF:5.168
170. Perez LE, Fernandez H, Ayala E, Beato F, Neuger A, Pidala J, **Schell MJ**, Anasetti C. Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic

- hematopoietic cell transplantation from mismatched unrelated donors. *Bone Marrow Transplant* 2017 Apr; 52(4):627-629. PMID: PMC5382111. IF:3.874
171. Han G, **Schell MJ**, Zhang H, Zelterman D, Puzstai L, Adelson K, Hatzis C. Testing violations of the exponential assumption in cancer clinical trials with survival endpoints. *Biometrics* 2017 Jun; 73(2):687-695. PMID: PMC6093291. IF:1.329
  172. Li J, Smalley I, **Schell MJ**, Smalley KSM, Chen YA. SinCHet: a MATLAB toolbox for single cell heterogeneity analysis in cancer. *Bioinformatics* 2017 Sep 15; 33(18):2951-2953. PMID: PMC5870537. IF:7.307
  173. Strom T, Harrison L, Giuliano A, **Schell M**, Eschrich S, Berglund A, Fulp W, Rhapa R, Coppola D, Kim S, Frakes J, Foekens J, Mule J, Torres-Roca J. Tumour radiosensitivity is associated with immune activation in solid tumours. *Eur J Cancer* 2017 Oct; 84: 304-314. PMID: PMC5822441. IF: 6.029
  174. Kumar NB, Patel R, Pow-Sang J, Spiess PE, Salup R, Williams CR, **Schell MJ**. Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer. *Oncotarget* 2017 Nov; 8: (58) 99093-99103. PMID: PMC5716795. IF:5.168
  175. Blackham AU, H Naqvi SM, **Schell MJ**, Jin W, Gangi A, Almhanna K, Fontaine JP, Hoffe SE, Frakes J, Venkat P, Pimiento JM. Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer. *J Surg Oncol* 2018 Feb;117(2): 150-159. PMID: 28833197. IF:3.151
  176. Davis TB, Yang M, **Schell MJ**, Wang H, Ma L, Pledger WJ, Yeatman TJ. PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation. *Sci Rep* 2018 Jun; 8: (1) 9296. PMID: PMC6006154. IF: 4.259.
  177. Rollison DE, **Schell MJ**, Fenske NA, Cherpelis B, Messina JL, Giuliano AR, Epling-Burnette PK, Hampras S, Amorrortu RP, Balliu J, Vijayan L, Naqvi SMH, Zhao Y, Parab K, McKay-Chopin S, Gheit T, Tommasino M. Cutaneous viral infections across two anatomic sites among a cohort of skin cancer screening patients. *J Infect Dis* 2018 Sep; In Press. PMID: 30260406. IF: 6.273
  178. Andreas Saltos, Farah Khalil, Michelle Motshman, Jiannong Li, **Michael Schell**, Scott Antonia, Jhanelle Gray (accepted). Clinical Associations of Mucin 1 in Human Lung Cancer and Precancerous Lesions. *Oncotarget*. 2018

#### Letters to the Editor, Comments

1. Reply to letter to the editor regarding "Hearing loss in children and young adults receiving cisplatin with or without cranial irradiation". *J Clin Oncol* 8:180, 1990.
2. Evans WE, **Schell MJ** and Pui C-H. MTX clearance is more important for intermediate-risk ALL. Letter to the editor. *J Clin Oncol* 8:1115-1116, 1990.
3. Pui C-H, **Schell MJ**, Raimondi SC, Head DR et al. Myeloid-antigen expression in childhood acute lymphoblastic leukemia. *N Engl J Med* 325:1378-1379, 1991. (letter.)

4. **Schell MJ**. Comment on "Bridging different eras in sports" *J Am Statist Assoc*, 94:681-684, 1999.
5. Bert H. O'Neil, MD, **Michael Schell**, PhD, Richard M. Goldberg, MD. Synchronous Colorectal Cancers: What's the Risk? *Clinical Advances in Hematology & Oncology*, 2(2), February 2004.
6. Yankaskas BC, **Schell MJ**, Miglioretti DL. Recall and detection rates in screening mammography (letter). *Cancer* 101(11):2710-2711, 2004.

#### Books

1. **Schell MJ**. Baseball's All-Time Best Hitters: How Statistics Can Level the Playing Field, Princeton University Press, 1999, 295 pp.
2. **Schell MJ**: Baseball's All-Time Best Sluggers: Adjusted Batting Performance from Strikeouts to Home Runs. Princeton University Press, 2005, 416 pp.

#### Technical Reports

1. **Schell MJ** and Leysieffer FW. Bivariate low dose extrapolation. Florida State University Statistics Report M762. July, 1987.
2. **Schell MJ** and Singh B. Power functions of likelihood ratio tests under order restrictions in normal means with three or four treatments. St. Jude Children's Research Hospital. Technical Report # 4, June, 1988.
3. Singh B, **Schell MJ** and Wright FT. The power functions of the likelihood ratio test for a simple tree order in normal means. St. Jude Technical Report # 5, December, 1988.
4. Singh B and **Schell MJ**. On power functions of the likelihood ratio tests for the simple loop order in normal means: unequal sample sizes. St. Jude Technical Report # 9, January, 1990.

#### Book Chapters

1. Mirro J, Crom W, Santana VM, **Schell MJ**, Belt J, Fridland A and Kalwinsky DK. AML trials at St. Jude Children's Research Hospital. *In: Acute Myelogenous Leukemia: Progress and Controversies*, R Gale (ed.). Wiley-Liss, New York, NY, pp. 219-227, 1990.
2. Kalwinsky DK, Raimondi SC, **Schell MJ**, Behm FG and Mirro J. Cytogenetic abnormalities in childhood AML. *In: Acute Myelogenous Leukemia: Progress and Controversies*, R Gale (ed.). Wiley-Liss, New York, NY, pp. 133-139, 1990.
3. Meyer WH, Pratt CB, **Schell MJ**, Fletcher BD, Marina N, Parham DM, Rao BN, Sandlund JT and Dahl G. The uses of ifosfamide as initial therapy in osteosarcoma. *In: Adjuvant therapy of cancer, Volume 6*, SE Salmon (ed.). WB Saunders, Philadelphia, PA, pp. 580-585, 1990.

4. McHaney V, Kovnar E, Meyer W, Furman W, **Schell M** and Kun L. Effects of radiation therapy and chemotherapy on hearing. *In: Late effects of treatment for childhood cancer.* DMGreen GJ D'Angio, (eds.). Wiley-Liss, New York, NY, pp. 7-10, 1992.
5. Haier RJ, Hazen K, Fallon J, Alkire MT, **Schell MJ** and Lott I. Brain imaging and classification of mental retardation. *In: Perspectives on fundamental processes in intellectual functioning.* S Soraci and WJ McIlvane, (eds.) Ablex Publishing, Stamford, CT, pp. 115-130, 1998.
6. **Schell MJ**, McBride MA, Gennings C and Koch GG. The intention-to-treat principle for clinical trials. *In: Clinical trials in neurology*, RJ Guiloff, (ed.). Springer London, pp. 131-144, 2001.

### **Book Reviews**

1. Curve Ball (J Albert, J Bennett, Authors) Springer-Verlag, 2001, New York. *Journal of the American Statistical Association* 2002, pg. 919.
2. Teaching Statistics Using Baseball (J Albert, Author) The Mathematical Association of America, 2003, Washington, D.C. *Mathematical Intelligencer*, 2005.

### **Research Interests**

Monotonic and nonparametric regression analysis, piecewise linear regression, changepoint analysis, order restricted inference, practice of statistics, cancer research.

### **Software**

An important aspect of introducing new statistical methods into practice is having user-friendly software available to the user. The following SAS macros are available to users or in development:

REDMON – (Programmer: Sean O'Brien) Obtains reduced monotonic regression estimates for a standard regression setting with a continuous dependent variable given. The theoretical underpinnings are given in Schell and Singh, 1997. Since 1998, over 300 individuals have accessed this macro. 15 page user's guide available. REDMON has been applied to real data in 5 published articles to date.

BREDMON – (Programmer: Sean O'Brien) Reduced monotonic regression for a binary dependent variable. A slight extension of theory from Schell and Singh, 1997.

ISO2VAR – (Programmer: Dan Scharf) An extension of reduced monotonic regression to the matrix order. A 24-page user's guide is available.

Two additional SAS macros, PIECELIN and MULTI-CHANGEPT, are currently under development as well.

### **Invited Lectures**

1. "Long-Term Effects to Treatment of Acute Lymphocytic Leukemia," Pediatric Cancer Family Retreat, October, 1992.

2. "Elements of Statistics and Avoiding Data Pitfalls," FHP Research Day, March, 1993.
3. "Survival Analysis," Long Beach Memorial Hospital, March 1994.
4. "Regression Analysis," Long Beach Memorial Hospital, March 1994.
5. "Statistics in Cancer Research," a lecture to Cancer Education Program (CEP) students, Summer 1997-1999. (3 times)
6. "Tony Gwynn – Baseball's Best Pure Hitter: A Statistical Analysis," University of North Carolina, September 17, 1997.
7. Book signings for "Baseball's All-Time Best Hitters," at Waldenbooks, Chapel Hill; Barnes & Noble, Durham; Regulator Bookshop, Durham; Barnes & Noble, Philadelphia.
8. Thirty-five radio and newspaper interviews on "Baseball's All-Time Best Hitters."
9. "Discussant for "Bridging Eras in Sports," American Statistical Association, Joint Statistical Meetings, September, 1999.
10. "Baseball's All-Time Best Hitters," University of North Carolina Teague Residence Hall, April 4, 2000.
11. "Baseball's All-Time Best Hitters," Fortieth Anniversary of the Statistics Department of Florida State University, April 21, 2000.
12. "Baseball's All-Time Best Hitters," University of South Carolina, March, 2001.
13. "Identifying a Target Recall Rate in Screening Mammography Using Reduced Monotonic Regression", Breast Cancer Surveillance Consortium Meeting, Santa Fe, NM, April 21, 2001.
14. "Statistical Issues in Clinical Trials," part of a Clinical Trials workshop for Oncology Fellows, Duck, NC, October, 2001.
15. "Association of Recall Rates with Sensitivity and Positive Predictive Values of Screening Mammography", Breast Cancer Surveillance Consortium Meeting, April 20, 2002.
16. "Do Statisticians Care How Users Analyze The Two-Sample Location Problem?", Duke University, May 15, 2002.
17. "Identifying the Best Home Run Parks in Baseball History", Statistics in Sports section of the ASA, Joint Statistical Meetings, August 12, 2002.
18. "Identifying Monotonic Trends in Data," Virginia Commonwealth University, February 18, 2003.
19. "Identification of Ideal Recall Rates for Screening Mammography," ENAR, Biometrics Society, Austin, TX, March, 2005.
20. "Identification of Ideal Recall Rates for Screening Mammography," Joint Statistical Meeting, August, 2005.
21. "Baseball's Best Batters: A Comparison of Models," Roundtable luncheon, Statistics in Sports Section, Joint Statistical Meetings, August, 2005.
22. "Piecewise Linear Regression," Korean-American Conference, Irvine, CA, August, 2005.
23. "Using Transformations to Obtain Improved Statistical Power," Grand Rounds in Population Science Series, Moffitt Cancer Center, October 2006.
24. "Screening Mammography and Best Ballparks for Home Run: Using Flexible Regression Approaches to Obtain Improved Estimation," North Texas Chapter of the American Statistical Association, Dallas, Texas, November 2006.



25. “Analysis of a small number of continuous biomarkers for identification of an efficacious drug-treatment response for individual patients,” ASCO, Chicago, IL, May 2008.
26. “Coors Field: Why Is The Home Field Advantage So High and What are its Implications,” Joint Statistical Meetings, Denver, CO, August 2008.
27. “Comparing Power Hitters Across Baseball History,” part of Steroids and Baseball Late-Breaking Session. Joint Statistical Meetings, Denver, CO, August 2008.
28. “Engaging in Statistical Practice in Academia is Honorable.” The 50<sup>th</sup> Anniversary Celebration of FSU’s Statistics Department, Tallahassee, FL. April, 2009.
29. “Improved Survival Modeling Using A Piecewise Exponential Approach,” Joint Statistical Meetings, Washington, D.C., August, 2009.
30. “Understanding Biomarker Data from Tissue Microarrays and Parametric Modeling of Survival: How Statistical Thinking Can Help the Oncologist,” Fox Chase Cancer Center, Philadelphia, PA, April, 2010.
31. “Identifying Key Advances to Improve Statistical Practice”, Statistical Practice in Cancer Conference, Moffitt Cancer Center, Tampa, FL, May, 2016
32. “Identifying Statistical Innovations Ready for Practice From The Literature”, Statistical Practice in Cancer Conference, Moffitt Cancer Center, Tampa, FL, March, 2017